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The year 2017, marks the 110th anniversary of the discovery of Alzheimer’s disease (AD)- a 
devastating neurodegenerative disease. Regardless of the significant advances made in the past 
century on the pathology of AD, the current pharmacotherapy options for AD remains woefully 
low and provide symptomatic relief only. Inhibitors of cholinesterase enzymes such as donepezil 
(Aricept®), rivastigmine (Exelon®) and galantamine (Razadyne®) which represents the primary 
class of agents used in the management of AD targets one of the many pathological routes of AD. 
Our study aims at discovering novel small hybrid molecules based on 3-phenylpyrazino[1,2-
a]indol-1(2H)-one (PPI) ring system which can potentially exhibit multiple activities toward 
various factors involved in AD pathophysiology  including (i) the inhibition of cholinesterase 
enzymes such as acetyl (AChE) and butyrylcholinesterases (BuChE); (ii) preventing the 
aggregation of the neurotoxic amyloid beta (Aβ) peptide and (iii) antioxidant properties.  Initial 
modeling studies suggested that the tricyclic PPI template fits in the catalytic site of AChE and 
the C3 phenyl can orient toward the peripheral anionic subsite (PAS) in the AChE enzyme. In 
addition, C3-position provides opportunities to incorporate Aβ binding pharmacophores.  
With this goal, we synthesized the PPI compound library by coupling ethyl indole-2-carboxylates 
esters with 2-bromoacetophenones to obtain ethyl-1-(2-oxo-2-phenylethyl)-1H-indole-2-
carboxylates which underwent an intramolecular cyclization in the presence of ammonium acetate 
to afford PPI derivatives (5a-n). The compounds were characterized by analytical methods 
including NMR and LCMS. The cholinesterase inhibition was evaluated using Ellman’s protocol 
by UV-Vis spectroscopy. The anti-Aβ-aggregation property was evaluated by fluorescence 




assessed using DPPH assay method. Transmission electron microscopic imaging (TEM imaging) 
were also performed to support the in vitro data obtained from ThT based fluorescence assays. The 
Discovery Studio (DS) software, Structure-Based-Design program (4.0) from BIOVIA Inc. was 
used to determine the binding interactions of the PPI derivatives for SAR optimization. 
Our results indicate that several compounds in the series exhibit dual cholinesterase inhibition 
properties; one such compound is 5h (3-(2-methoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one) with 
IC50 AChE = 7.3 μM , IC50 BuChE = 1.9 μM. Compound 5h was found to be much more potent 
than reference agents donepezil and rivastigmine toward BuChE inhibition. Several other 
compounds such as 5d ( 3-(3,4-dimethoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one) and 5h (- 3-(2-
methoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one exhibited excellent of Aβ40/42 inhibition (% 
inhibition of Aβ40 = 83.3% and 67.7% at 25 µM respectively, and % inhibition of Aβ42 = 90% and 
94% at 25 µM respectively).  Compound 5d and 5h were found to be more potent than curcumin 
and resveratrol towards Aβ42 inhibition. The PPI derivatives were also found to exhibit antioxidant 
activities. Unsubstituted PPI compound 5a exhibited good antioxidant activity (~33% DPPH 
radical scavenging at 50 μM), while, compound 5k (3-(4-hydroxy-3-methoxyphenyl)pyrazino[1,2-
a]indol-1(2H)-one) exhibited excellent antioxidant activity (~ 84% DPPH radical scavenging at 
50 μM). This proves the multi-targeted activities of PPI derivatives.   
Our results indicate that the fused tricyclic phenylpyrazino[1,2-a]indo-1(2H)-ones (PPI) represent 
a novel class of compounds which can be modified chemically to design and develop multi-
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Chapter 1. Introduction 
1.1 Dementia  
“Dementia” as a medical term is in use to describe the overall decline in the mental, behavioral 
and task completion activities of an individual. Patients with dementia find it tough to perform 
everyday activities such as making meals, traveling, to name a few. Moreover, a sharp decline in 
the behavior of a person along with impairments associated with speech, memory, recognition of 
the language, ability of a person to judge the situation wisely, can be observed easily.1 Dementia 
can be caused by various associated diseases such as Alzheimer’s disease (AD), vascular dementia, 
dementia with Lewy bodies, mixed dementia, frontotemporal lobar degeneration, Parkinson's 
disease, Jacobs’s disease and Normal pressure hydrocephalus.2 
According to a recent survey for 2016, in Canada, there are about 564,000 Canadians who are 
suffering from dementia. These numbers have been estimated to elevate to 937,000 by the year 
2030.3 An evaluation of the statistics reveals that the Canadian government spends about CDN$ 




Medically to determine if a patient has dementia, physicians usually refers to a manual known as 
Diagnostic and Statistical Manual of mental disorder (DSM). According to DSM, dementia is 
categorized as a prime Neurogenerative Disorder (NDD) as it impairs the cognitive functions as 
well as performing everyday activities of the patient.4 Assessing whether a patient has dementia is 
a lengthy and expensive process and usually, involves two different approaches for assessment of 
the dementia prevalence. The first one being the early process of evaluation which includes 
questionnaires based on family history of dementia, change in behavior, mental state examinations 
to name a few.5 Neuropathological lab testing- autopsy, being the another confirmatory and 
classifying test which is used to distinguish between the various types of dementias.6 Proper 
evaluation of a patient who has dementia is critical as for each type of dementia, a different kind 
of treatment is used. In many cases, a patient can be misdiagnosed for dementia for having 
dementia type symptoms. Misdiagnosis is very common in patients suffering from depression, 
delirium, thyroid problem, and alcohol toxicity2 as the symptoms mimic dementia.  In a national 
survey, it has been estimated that misdiagnosis of dementia (Alzheimer’s disease in particular) can 
be as high as 67.1% with 18.2% of the misdiagnosed patients receiving inappropriate medications.6   
Hence, in brief, we can say that dementia is a multifaceted neurodegenerative disorder which 
causes adverse effects on memory, emotions and daily activity. 
1.2 Neurodegenerative Disorder (NDD) 
Neurodegenerative disorder (NDD) is the pathological condition of the brain in which there is an 
extensive dysfunction of the nervous system, leading to the death of the neuronal cells.7,8 The 
reason for such a catastrophic destruction of the neurons can be:  
 sporadic- may be due to infection.  




 Protein misfolding and aggregation- the induced defect in the structure and function of the 
neurons caused by misfolded and aggregated proteins leading the cells to disrupt and 
rupture.  
The misfolding, accumulation and aggregation of certain detached surface proteins, such as 
amyloid beta(Aβ) protein and tau protein in Alzheimer’s disease; alpha-synuclein in dementia with 
Lewy bodies and Parkinson’s disease and so forth, are the examples of misfolded and aggregated 
proteins causing neurodegeneration. These proteins, which under normal conditions, are present 
as an integral part of the neurons and whose detachment and aggregation causes the cells to 
undergo neuronal death accelerates the progression of NDD.9 More discussion of the individual 
proteins (amyloid beta and tau protein) and how these proteins cause progression of 
neurodegeneration in presented in appropriate segments of this thesis. 
1.3 Alzheimer’s disease (AD) 
Alzheimer’s disease is considered to be the most prevalent form of NDD and accounts for about 
80% of all the registered cases associated with NDD and the leading cause of death associating 
dementia.2 AD was first identified in 1907 by Alois Alzheimer, a German neurologist, and 
psychiatrist.10 Even after around 110 years of its discovery, little is known about AD’s inception2 
even though, there have been many theories which explain the progression of the disease. We will 
be discussing the individual theories in appropriate sections in this thesis.     
1.3.1 Detection of AD: According to the DSM criteria, the changes in the brain morphology of 
the patient suffering from AD initiates much before the actual symptoms start to appear. Hence, it 
is believed that to prevent, slow or stop the disease, early detection is crucial4 which till now is not 




available. Usually, a doctor along with a neurologist assess the patient using a variety of tools to 
help make a diagnosis. Tools which are often utilized for the determination are as follows:  
 Evaluate the family history of the patient for AD.  
 Psychiatric history and behavioral changes estimation. 
 Evaluation of mental state by conducting cognitive and behavioral tests. 
 Laboratory tests: by performing blood tests and brain imaging.  
Even after using an array of diagnosis, it will take lots of time before a physician can make any 
diagnosis.2 
1.3.2 Diagnosis: Early symptoms of AD varies among individuals, though, difficult to remember 
newer information being the most common among the patients. This is because the neuronal and 
synapses loss starts in the cerebral cortex and subcortical regions of the brain, which is associated 
with processing newer information.11,12 Other initial symptoms of AD are as follows:  
 Confusion with the place, time and face recognition.  
 Understanding in language recognition.  
 Mood swings and initiation of split personality behavior. 
 The decline in situation judgment. 
 Elevation in anxiety and agitation. 
 Poor control over sleep.  
1.3.3 Changes in brain morphology: A healthy brain of an adult contains approx. 100 billion 
neurons connected to each other by more than 100 trillion synapses. This secure interconnection 
between the neurons helps the brain to function properly by allowing the neurotransmitters to pass 




decline in the mental ability occurs which can be compiled by the individual effects of Aβ 
accumulation, reduction in the levels of neurotransmitters in the brain, generation of 
neurofibrillary tangles (NFTs) by dead neurons, and a decrease in the number of synapses (Fig. 1-
1). The overall effect of neuronal death causes an average decline of brain volume by 5.3% (decline 
in gray matter volume only) over a period of at least one year.13  
 
Figure 1-1: Comparison between the microscopy of (a) healthy brain  (b) Brain of an AD patient- 
one can see the accumulation of Aβ plaques and NFTs. 
1.4 Initiation of AD 
Although AD has been categorized as an age-dependent progressing disorder, genetic 
abnormalities have found to play a significant role in determining the susceptibility of a patient to 




 Sporadic AD – This type of AD progression is the most common form of AD and accounts 
for almost 99% of the cases. The progression of the disease state is dependent on various 
physical and environment factors.  
 Familial AD – AD progression is based on the genetic factors such as down syndrome, 
genetic mutations, etc.  
1.4.1 Familial AD: Alzheimer’s disease progression due to genetic variations 
 
It has been estimated that less than 1% of all the cases of AD are linked to genetic changes, causing 
the progression of AD.2 Three specific genes have been linked with AD progression. Any 
abnormal mutations in the genes linked to Amyloid precursor protein (APP), presenilin-1 and 
presenilin-2, increase the risk of development of AD by 90-95%. It has been observed that patients 
with such mutations tend to develop the disease at an early age, which can be as early as 30 years.2  
Down syndrome (DS): This syndrome is caused by the presence of an additional copy of 
chromosome no. 21 in the genome of a person. Individuals with DS has been reported to have 
higher chances of developing AD-like pathophysiologies at an early age of around 40 years. 
Statistically, more than 75% of the people with DS suffer from AD. A clear link has yet to be 
identified but, researchers assume that the presence of an additional copy of chromosome 21, 
which also is the locus of the gene encoding for APP, could double the hydrolysis of APP and 
thus, elevates the risk for developing AD.2  
1.4.2 Sporadic factors leading to AD:  
 
Chronic type initiation of AD is considered to be the most common form of AD among patients, 
and experts believe that this can be due to the combined effect of various related/ interrelated 




 Controllable factors 
o Cardiovascular disease risk factors 
o Education  
o Social and cognitive engagement  
o Traumatic brain injury 
 Uncontrollable factors  
o Age  
o Family history  
o Activation of APOε4 gene 
1.4.2.1 Controllable Factors: Controllable factors, as the name suggests, can slow down the 
progression of AD. As we know that AD is an age-dependent disease; aging cannot be stopped. 
Thus, it would be much easier to control the health-related factors such as diabetes, obesity, 
cardiovascular diseases, etc. to delay the onset of AD. A recent study aimed to find a link between 
physical activity and cognition/dementia. Not much of a surprise,  it was observed that regular 
physical activity not only helped manage the cardiovascular risk factors such as hypertension, 
obesity, diabetes and smoking, it also significantly contributes to reducing the risk of cognitive 
decline and dementia2.  
Having an active social life have also been linked to a healthy brain function. Isolation of an 
individual not only hinders personal growth, but it can also affect one's brain in a negative way. 
Such people are at higher risk of developing dementia. The exact mechanism and a scientifically 
valid reason are yet to be explained. Similarly, education level of an individual has been 
proportionally linked to the modified risk of dementia. According to the cognitive reserve 




involved in formal education, can compensate for the modifications caused by AD and can trick 
the neurons in making alternate routes for interneuronal communication required for cognitive 
functions. This can lead to a decline in the symptoms of AD as the aging progesses.2  
Uncontrollable factors: Uncontrollable factors such as age, family history, and apolipoprotein E-
ε4 (APOE4) gene activation are some of the uncontrollable factors which possess the greatest risk 
factor for the delayed onset of the AD in more than 95% of the reported cases.  
Age: Even though aging is one of the most significant risk factors for the development of AD, it 
is not the standalone for causing the disease. Also, AD is not a common outcome of aging as well. 
People with sporadic AD lie in the age bracket of 65 and older, and as the age increases, so are the 
chances of developing AD. That is why AD is considered as an age-dependent disease.2  
Family history: It has been observed that first degree relatives with similar heredity conditions, 
similar and shared environmental and lifestyle conditions and whose at least one family member 
is suffering from AD have higher chances of developing AD in the later stages of their life. The 
family history may or may not be linked to the activation of the APOE4 gene as explained by some 
researchers.2  
Inheritance of APOE4 gene: The APOE4 gene,  is located on chromosome 19 and is responsible 
for the production of cholesterol transportation protein APOE. Isoforms of APOE gene are known 
to regulate Aβ aggregation and clearance in the parenchyma of the brain. APOE genes are also 
known to play a role in the regulation of glucose metabolism, lipid transportation in and out of the 
brain, mitochondrial function,  neuron signaling and neuroinflammation.14  Three very common 
forms of APOE genes are ε2, ε3, and ε4 are known and one of them is inherited to the offspring 




six possible APOE forms which are ε2/ ε2, ε2/ ε3, ε2/ ε4, ε3/ ε3, ε3/ ε4, ε4/ ε4. Out of all the 
possible APOE forms, people who inherit ε4/ ε4 allele are at 8 to 12 fold higher risk than the one 
with ε3/ ε3 gene and are more prone to develop AD at early stages of life. While it is noticed that 
people with ε2/ ε2 gene have reduced the risk of developing AD at later stages of life as compared 
to people with ε3/ ε3 gene. Though these speculations are just observation and no precise 
mechanism between  APOE genes and AD risk is not clear.2  
1.5 Biomarkers for AD detection  
As the number of patients suffering from AD is increasing every passing day, and due to the non-
availability of any preventive and curing regime, it is important to delay the progression of the 
disease as soon as the condition is detected. As, the symptoms of AD starts at a very late age, 
sometimes as late as when more than 40% neurons have already been degraded, it is important to 
get a hold on to the disease as early as possible. To do so, biomarker detection for AD at early 
stages can be an excellent option to hinder the progression of the disease.15,16 
Biomarkers, as we know, when present in a concentration higher than the standard concentration 
can be associated with the disease. Diagnosis of such biomarkers helps in monitoring and 
progression of the illness. For a particular condition, there are specific biomarkers which have 
been recognized, detected and biochemically evaluated.17 Similarly, for AD, various imaging 
techniques- used for direct visualization of brain function, and peptide biomarkers- present in 
plasma, cerebrospinal fluid (CSF) and urine, can help in evaluating the disease progression.15,18   
Currently, there are three classes of biomarker detection methods which are available (imaging 
techniques), and some are  still under development (biochemical peptide detection) which can be 





Figure 1-2:Classification of biomarkers used in AD detection. 
   
1.5.1 Imaging: Imaging techniques such as CT scan, PET scan, PIB-PET scan and MRI scan can 
help in estimating changes in the morphology of any region of the brain .18 A simple visual 
comparison between CT/ PET scan of an AD patient with a healthy brain scan can be used in 
evaluating the stage of AD.19   
Biochemical estimation of a particular peptide or a specific factor (a specific type of peptides) can 
also be used in evaluating the AD progression. For such assessment, plasma and CSF are used, 
and via series of biological laboratory tests, the concentration of such biomarkers can be estimated 
which can be correlated with the imaging biomarkers to make a concrete decision about the stage 
of the disease, and also to determine the type of dementia, the patient is suffering. E.g. one can 
clearly distinguish between a patient suffering from AD and Parkinson disease by comparing the 
imaging and clinical examination.15,19,20 
1.5.2 Plasma: Biomarkers present in plasma which is specific for AD are α-macroglobulin, 
component factor H, α1-antitrypsin, α1-antichymotrypsin  and Aβ species. Even though the 
estimation of such biomarkers can be performed relatively quickly,  the success of such estimates 
Biomarkers for 
AD detection 




has limited value as various laboratories use different techniques for determining such markers 
and thus, lacks specificity,  sensitivity, and reproducibility. The Aβ species present in blood plasma 
can readily be determined using ELISA, and clinical correlation of such data cannot be made to an 
actual disease state as Aβ in plasma is derived from peripheral tissues which are not correlated 
with brain Aβ load and no assessment can be done with brain Aβ production.15,18  
1.5.3 CSF biomarkers: CSF or cerebrospinal fluid is a semi-viscous fluid which is present in the 
subarachnoid space and ventricular system and acts as a cushion against mechanical injuries to the 
brain. Because of the direct contact of the CSF to the brain, the presence of any proteins in CSF 
could be directly  related to the brain activity and can thus CSF could be expected to serve as an 
excellent source of biomarkers for AD.15 However, in various studies performed by different 
groups, it was observed that levels of Aβ42  change according to the type of protocol used for assay. 
In most of the reports, a slight decrease in the levels of Aβ42 has been observed, and this can be 
explained by the accumulation of Aβ42 to form plaques (known as amyloid sinks)18, and thus, a 
decline in the Aβ42 concentration in the CSF can be seen. This observation was further supported 
by an increase in the plaque burden as observed by positron emission tomography (PET) imaging. 
In the case of Aβ40, no such change in the concentration was observed. It has also been noticed 
that a decrease in the ratio of Aβ42/ Aβ40 could be more statistically relevant observation than 
studying the reduction of Aβ42 alone. Thus, to conclude, we can say that biomarkers can become a 
source of early detection of AD progression and the methods are yet to be standardized so as to 
provide a reliable and reproducible data which can be clinically correlated with AD.15  
1.6 Currently available treatment for AD 
In the present scenario, AD treatment is challenging as currently approved medications only 




in the brain2 or cure AD. Presently, there are only four FDA-approved drugs which can be used in 
the management of AD2, and those are (Fig. 1.3): 
                                                           
  
 
                                                                                    
 
Figure 1-3: Molecular structures of (a) Donepezil (b) Galantamine (c) Memantine                     
(d) Rivastigmine. 
All the medications mentioned above, except for memantine, targets cholinesterase enzymes; 
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) and provide symptomatic relief 
to the patients by maintaining the levels of a neurotransmitter known as acetylcholine (ACh) in 
the brain. These medications are either used alone or in combination with other drugs to provide 
symptomatic relief to the patients.2,9 Some of the treatments currently in use for AD patients are 
as follows:  
1.6.1 Monotherapy by AChE and BuChE inhibitors: Monotherapy by one of the approved FDA 
drugs such as donepezil, galantamine, and rivastigmine are usually used in the management of 







dependent manner.21 Initiation of treatment with cholinesterase inhibitors (ChE)  inhibitors at early 
stages of AD with drugs such as Aricept® also known as donepezil or Razadyne® also known as 
galantamine prevents rapid onset of symptoms associated with AD. Donepezil, a potent 
benzylpiperidine compound, exhibits high selectivity towards AChE with its IC50 value for AChE  
~9 nM while for BuChE the IC50 value is ~1000 nM. Galantamine, on the other hand, is an alkaloid 
which was first isolated from flowers and bulbs of plant known as Galanthus. Similar to donepezil, 
galantamine also exhibits selectivity towards AChE with an IC50 value of ~0.2 μM. Galantamine 
is 50-times more selective for  AChE compared to BuChE.  The in vivo half-life (t1/2) for both 
donepezil and galantamine are 70 h and ~ 6 h respectively. As half-life for donepezil is around 
three days, this gives an edge over galantamine by reducing the dose frequency and thus, fewer 
side effects and hence, is used in all stages of AD, while, Galantamine is used in mild to moderate 
AD because of higher dosing frequencies.9  
1.6.2 NMDA receptor antagonists: N-methyl-D-aspartate receptors (NMDA) can be categorized 
as ionotropic glutamate receptors and are ligand-gated ion channels present on the surface of 
neurons. Overexcitation of these receptors is known to have calcium ion induced toxic effects 
which lead to the death of the neuron.22  Normal activation of NMDA receptors is essential for 
maintaining the proper activity of the brain. However, overactivation of NMDA receptors, as 
observed in AD, is associated with excess intake of Ca2+ ions in the intracellular region. This 
overburden of calcium ions triggers a cascade of downstream events which results in 
neurodegeneration. NMDA receptor antagonists such as memantine have been reported to be 
useful in the treatment of AD.23,24 
1.6.3 Combination therapy: Namzaric®,  which contains a mixture of donepezil HCl (10 mg) 




Unfortunately, this is the only combination therapy available for AD management . 2,25 The 
superiority of this type of therapy was supported by a randomized, double-blind placebo-controlled 
study which took over a period of  24 weeks. This clinical study concluded that an added advantage 
is achieved over single drug administration of either donepezil or memantine. A definite 
improvement in cognition and behavioral aspects of the patients was observed when donepezil and 
memantine were given as a combination therapy as compared to patients receiving donepezil or 
memantine alone.26   
1.7 AD hypothesis  
AD initiation and progression has been explained by various hypotheses.9,27 Among these, the 
cholinergic hypothesis is the earliest known theory which was put forward in mid-1970’s.28 
Amyloid beta (Aβ) hypothesis, was presented in 199129; Tau hypothesis and mitochondrial 
dysfunction are among others.27,30 Because all these theories help to explain the different 
pathological observations in AD, these hypotheses are considered as a primary hypothesis for AD. 
For example, the cholinergic hypothesis helps account for the role of acetylcholine (ACh); one of 
the neurotransmitters in the brain in learning and memory.The deficits of ACh (frequent 
observations in AD patients) is responsible for memory loss in AD patients28 while the Aβ 
hypothesis explains the accumulation of senile plaques in both extracellular as well as intracellular 
regions of the brain. 31 Tau hypothesis, on the other hand, explains the presence of neurofibrillary 
tangles (NFT’s) in intracellular regions of the brain.30 There are other theories which have been 
put forward and helps account for the correlation of pathological observations as secondary 
hypotheses. The examples of secondary hypotheses are oxidative stress, inflammation, cholesterol 
hypothesis and Aβ pore formation (Fig. 1-4). Relationship between Primary and secondary 




can be described by caspase-mediated cell death which can be initiated by oxidative stress 
(secondary hypothesis). 
 
Figure 1-4: Various hypotheses for AD. Hypothesis marked in red (viz. cholinergic, tau, amyloid 
beta and oxidative stress) are considered as a primary hypothesis for AD. While, hypotheses given 
in green (viz. mitochondrial dysfunction, inflammation, cholesterol hypothesis and amyloid beta 
pore formation hypothesis) are considered as a secondary hypothesis. 
1.8 Cholinergic Hypothesis 
As stated earlier, the cholinergic hypothesis is one of the earliest known hypotheses put forward 
for AD which correlates the function of ACh- a neurotransmitter, in learning and memory.28  
According to this hypothesis, cholinergic neuron degeneration in the forebrain, cerebral cortex and 
other associated areas of the brain results in loss of cholinergic neurotransmission and thus, 
significantly contributes to the loss of ACh-dependent cognitive function as observed in AD 




cholinergic neuron degeneration. To make the situation worse, two ACh hydrolyzing enzymes 
AChE) and BuChE further reduces the level of ACh.32,33 Under normal conditions, AChE, which 
is present on the post-synaptic membranes in the neuromuscular junctions, helps in terminating 
the excess signal transmission by hydrolyzing ACh and thus preventing overexcitement of the 
postsynaptic neurons. In the case of cholinergic neuronal degeneration, the ACh levels are already 
marginalized, and further hydrolysis of ACh by AChE significantly reduces the ACh levels which 
compromise the cognitive functions. To eliminate this situation, various small molecules have 
been developed which acts as cholinesterase inhibitors which bind to these enzymes and thus 
prevent the hydrolysis of ACh.9,28,33,34 These small molecules are known as cholinesterase 
inhibitors (ChEIs) and form the first and the only line of therapy currently available for AD 
management.35 E.g. of cholinesterase inhibitors approved by FDA for AD management are 
donepezil (Aricept®), (S)-rivastigmine (Exelon®) and galantamine (Razadyne®).9 
1.8.1 Cholinergic neurotransmission 
 
Neurotransmission in cholinergic neurons depends on ACh as a neurotransmitter to initiate and 
transmit signals between cholinergic neurons. ACh is synthesized in the cholinergic nerve endings 
from acetyl CoA and choline using choline acetyltransferase (ChAT) as the catalytic enzyme. 
Upon synthesis, ACh gets stored in vesicles. Vascular ACh transporter (VAChT) is the carrier 
responsible for entry of ACh into the storage vesicles. Such transportation is facilitated by ATPase 
and H+ gets countertransport (outside the vesicles) keeping the iso-osmotic and electroneutrality 
intact. ACh remains stored within the vesicles till there is no action potential generated by the 
neurons. Once a neuron gets excited (action potential is generated), neuronal membrane 
depolarization takes places by the influx of Ca2+ ions through calcium channels. The elevated 




proteins (VAMPs). The fusion of vesicles to the VAMP’s result in the release of ACh by the 
process of exocytosis.36  When ACh enters the synaptic cleft, it can trigger action potential on the 
postsynaptic neuron by interacting with nAChR (nicotinic Acetylcholine receptors) or mAChR 
(Muscarinic Acetylcholine receptors). The nAChR’s are associated with the Peripheral Nervous 
system (PNS), Central Nervous system (CNS) and neuromuscular junctions (NMJs). While 
mAChR’s are specifically for PNS but are also present throughout the body (Fig. 1-5).36  
ACh which was not being able to generate an action potential gets hydrolysed by AChE enzymes 
to choline and acetate. The choline released by the hydrolysis of ACh gets recycled and enters the 
neuron using Na+- choline co-transporter.36  
Various studies indicated that in AD, substantial deficits in ChAT levels (the enzyme responsible 
for the synthesis of ACh). The choline reuptake and ACh release get hindered. The combined 
effects of which results in a presynaptic cholinergic deficit,28 thus marginalizing the levels of ACh 
in the nervous system. The decrease in the levels of ACh results in learning and memory 




              




 The AChE enzyme (Fig.1-6) (EC 
3.1.1.7) can be categorized as a serine 
hydrolase. This enzyme is found both in 
the CNS and PNS as an ACh 
hydrolyzing enzyme 34,37 AChE is fully 
capable of working efficiently as a 
monomer; other isoforms of the 
enzyme are also known to be present 





in different areas throughout the body. Eg.  GPI- anchored dimeric structure of AChE is present 
on the surface of erythrocytes, while, in CNS, the enzyme is present in tetrameric form.9 
AChE is the primary target for the anticholinesterase drugs such as donepezil, galantamine, and 
rivastigmine. The gene responsible for the production of this enzyme is localized to human 
chromosome 7 (7q22).38 
1.8.2.1  Molecular structure of AChE  
 
The high catalytic activity of AChE towards various inhibitors can be explained by its unique 
design of the active site. The X-ray crystallographic studies and site-directed mutagenesis are 
among the techniques which have been 
utilized for the characterization of amino 
acid residues, present in the active gorge 
of AChE. The shape of the active site 
gorge is observed to be similar to a 
bottleneck and as a horseshoe. The 
active site is present 20 Å below from 
the entrance (Fig. 1-7).       
Figure 1-7: Subsites for the AChE enzyme. Amino acids in yellow represent the catalytic triad. 
Amino acids in green represent the acyl pocket. Amino acids in red represent the hydrophobic 
subsite, while, the amino acids in orange represents the peripheral anionic site.    





Various subsites of the active site that play an important role have been reported.9 The subsites for 
the human AChE (hAChE) can be defined as follows (Fig. 1-7).  
 Catalytic triad [Ser203, His 447, Glu334]38  
 Acyl pocket [Phe295 , Phe297]39 
 Hydrophobic subsite [Trp86, Tyr133, Tyr337, Phe338]38 
 Peripheral anionic site [Tyr72, Asp74, Tyr124, Trp286, Tyr341]32 
Catalytic triad represents the three main amino acid residues which are responsible for the 
hydrolysis of ACh. Acyl pocket, on the other hand, helps in stabilization of the acetyl group of the 
ACh.  A subset of 14 amino acids at the entrance of AChE enzymes consisting of aromatic amino 
acids such as Tyr and Trp represent the peripheral anionic site (PAS). Some studies suggest that 
blocking the activity of PAS will help in preventing AChE-induced aggregation of Aβ.9 
1.8.2.2 Hydrolysis of ACh by AChE 
 
In the synaptic cleft, as soon as ACh gets released from the presynaptic cleft, it is subjected to 
hydrolysis by AChE. It has a very high specific catalytic activity.One AChE enzyme molecule is 
known to hydrolyze about 25,000 molecules of ACh per second.40  Hydrolysis of ACh by AChE 
can be considered as a stepwise mechanism which involves the formation of one intermediate and 
two transition states.41,42 In the first step, a proton transferred from Ser 203 to His447 takes place 
which results in the formation of deprotonated Ser203 and protonated His447 species. In the 
second step, a nucleophilic attack by deprotonated Ser203 to the carbonyl carbon of ACh results 
in the formation of a zwitterionic form of acyl-enzyme intermediate. In the final step, the acetylated 




               
Figure 1-8: Hydrolysis of ACh by AChE 
   
1.8.3 BuChE  
 
Butyrylcholinesterase (BuChE) also known as acylcholine aceylhydrolase, or 
pseudocholinesterase (EC 3.1.1.8) is a homologous analog of enzyme AChE and belongs to the 
class of α/β fold family, similar to AChE. This means that the structure of BuChE, as well as 
AChE, contains a central β sheet which is surrounded by α-helix.43 This enzyme is known to 
hydrolyze choline substrates such as butyrylcholine (BuCh) specifically and can also hydrolyze 
ACh, but at a lesser efficiency. Moreover, BuChE is also known to hydrolyze non-choline esters 
such as cocaine, aspirin, and heroin.43  BuChE is found primarily in the organs of the body such 
as heart, liver, kidneys, lungs, intestine, as compared to AChE, which is present predominantly in 
the synaptic cleft of the neurons.44 It has been reported that in certain species including humans, 
horse, and mice, higher activity of BuChE has been observed in plasma than AChE. While, in 




species, the enzyme biosynthesis takes place in the liver which can then diffuses in the plasma and 
thus, those animal species show the higher activity of BuChE in blood plasma. The primary 
function of BuChE in plasma is still unclear, but, it has been observed that in the case of ingestion 
of nerve poisons such as organophosphates (OP’s), BuChE is known to scavenge to OP’s and thus 
helps to prevent OP mediated toxicity.43,44 Apart from the role of BuChE as a safety net for 
protecting the cholinergic transmission from various nerve poisons, it has also been a target for the 
activation of some prodrugs into their active forms. Bambuterol is one such example which is 
hydrolyzed by BuChE to give terbutaline, which has substantial antihistaminic activity. Similarly, 
heroin is converted to 6-acetylmorphine by the action of BuChE. The metabolized form of heroin 
is t lipophilic enough to cross the blood-brain barrier (BBB) and gets metabolized further to 
produce morphine in the brain. It is interesting to note that BuChE is the only enzyme present in 
the human blood plasma which can hydrolyze heroin.44   In the brain, BuChE gets synthesized by 
glial cells and accounts for around 10% of the total cholinesterase activity in a healthy brain.45 It 
has been observed that in AD, there is almost 50% reduction in the brain AChE levels at the later 
stages of the disease, while, the predominance of BuChE elevates to 90% and thus, BuChE 
inhibition forms an essential target for the disease, particularly in the later stages of the disease. 
As far as homology is concerned, BuChE and AChE share a structural and functional resemblance. 
The amino acid sequence homology between BuChE and AChE is around 65%, and the gene 
responsible for the production of BuChE was found to be localized on human chromosome 3 
(3q26).46  
1.8.3.1 Active sites in BuChE 
 
The monomeric structure of BuChE contains 574 amino acids with a few asparagine-linked 




globular structure of BuChE. Unlike the structure of AChE, BuChE contains a much larger active 
site with 55 amino acid residues. It is almost 60% larger compared to AChE active site volume 
(~501 Å3 vs. 302 Å3).The amino acid residues from different subsites which can be categorized 
into: 
 Catalytic triad (esteric site) – includes His438, Glu325, and Ser198 
 Acyl Pocket or acyl binding site -  Contains Leu286 and Val288 
 Choline binding site (cation- π site) – contains Trp82, Tyr337 
The catalytic triad in BuChE also contains 
three amino acids namely histidine, serine, 
and glutamic acid. The function of these 
amino acids is known to be similar to 




Figure 1-9: Key amino acids in the BuChE binding site.  
 
Acyl pocket in BuChE contains two primary amino acids namely leucine and valine. These 
aliphatic amino acid residues allow the entry of larger molecules such as butyrylcholine (BuCh) 
or other large acyl group containing compounds into the active subsite of the BuChE enzyme. This 
observation is different from AChE as the active subsite of AChE contains larger aromatic 




as compared to 501Å3 volume of the active gorge in BuChE. This larger size of the active gorge 
allows the entry of larger molecules in the active site of BuChE.47  
Comparing the fourteen (14) amino acids present at the entry of the cholinesterase enzymes, 
AChE’s amino acids residues are bulky and aromatic in nature which forms the part of PAS. In 
BuChE, half of these amino acid residues are aliphatic in nature and thus allows BuChE more 
flexibility and less steric hindrance so that even large molecules could reach to the active site of 
the enzyme. When compared to the active site of cholinesterase enzymes,  BuChE’s active site is 
around 200Å3 bigger than active site of AChE44,47 because of the presence of aliphatic amino acid 
chains in the active site of the enzyme. 
1.8.4 Conclusion derived from cholinergic hypothesis 
 
Acetylcholine (ACh) forms an empirical part of the cholinergic neurotransmission, and appropriate 
level of this neurotransmitter is required to maintain homeostasis. Reduced level of ACh in the 
brain due to neuronal loss is linked to the loss of memory and cognition. Two cholinesterase 
enzymes namely AChE and BuChE are capable of hydrolyzing ACh with AChE playing the 
primary role. The BuChE’s contribution to the hydrolysis of ACh is around 10%.  In AD, to 
maintain an acceptable level of ACh, the only current possible way is to inhibit the activity of these 
cholinesterase enzymes. As discussed earlier, the activity of BuChE increases as the disease 
progresses, it is thus essential to target BuChE so as to maintain healthy ACh levels at the later 
stages of the disease. Therefore dual inhibition of AChE and BuChE is desired. Currently, all 
available FDA-approved AD treatments prevent the hydrolysis of ACh by inhibiting both AChE 
and BuChEs. Donepezil, rivastigmine and galantamine are some of the examples of  ChEIs. In 
conclusion, ChE inhibitors provide only symptomatic relief and are effective as a long-term 




1.9 Amyloid Beta (Aβ) Hypothesis  
The occurrence of some unusual metabolic substances in the brain, which according to Alois 
Alzheimer, stain differently from healthy neurons, and the pathology which he then described does 
not fit with any of the disease known during that time.48 Based on a series of research findings 
initiated by Alois Alzheimer’s, the amyloid beta hypothesis was then put forward by Hardy and 
Allsop in 1991.31,48 It was based on the fact that a protein like material whose deposits were found 
in the meningeal vessels of the brain of an AD patient, was found to be  identical to the protein 
found in patients with Down syndrome, and the same was also the part of the senile plaques formed 
a link between Down syndrome and AD.31 More details about the correlation between AD and 
Down syndrome is explained in the next section of this thesis.  
  The Aβ hypothesis remains the best scientifically supported theory used to describe AD.31 
According to this hypothesis, the progression of AD can be attributed to the progressive 
accumulation and aggregation of small peptides either extracellularly or intracellularly or both. 
Such aggregates are made up of a peptide with 40 to 42 amino acid chain length, and these peptides 
tangle to form insoluble quasi-crystalline deposits of amyloid fibrils. Further aggregation of these 
fibrils in a circular manner results in the formation of senile plaques or neuritic plaques (Fig.1-10). 
This type of aggregate can be either self-induced or promoted by AChE, as hypothesized by some 






Figure 1-10: Steps in the aggregation of Aβ monomer to oligomers and fibrils. 
Senile plaques contain aggregates of Aβ as the core while, activated microglia, dystrophic neurites, 
and reactive astrocytes form the outer covering, and thus senile plaques form extracellular lesions 
of the brain.12  In 1984, Glanner and Wong became the first researchers to report the purification 
and partial structure of Aβ, which they named amyloid β protein51 and soon after, a complete 
peptide sequence structure of the Aβ was reported. It was in early 2002 that Nussinov group first 
published the 3D model of Aβ16-35 oligomers. The structure of the oligomers was reported to have 
a bent structure: U-shape, due to the presence of an intermolecular salt bridge between Asp23 and 
Lys28.52 This molecular structure was described using molecular modeling studies and then 
confirmed by solid-state NMR analysis in 2006 by Tycko and coworkers. In 2015, the complete 




1.9.1 AD and Down Syndrome: is there a connection between these two distinct diseases?  
 
As mentioned before, the Aβ protein- whose molecular weight was found to be four kDa, was also 
found in patients suffering from Down Syndrome; along with neurofibrillary tangles, indicating 
that there are a strong connection and common origin of both the diseases.12  Genetic studies on 
patients with AD and Down Syndrome also supported this observation. Beyreuther and coworkers 
in 1987 cloned a gene responsible for the expression of amyloid precursor protein (APP) and found 
it to be localized on the long arm of chromosome 21. Interestingly, in Down Syndrome, an extra 
chromosome 21 (and thus, known as 21 trisomy) is present. Hence, one would expect that due to 
the presence of an additional set of chromosome 21 in Down syndrome patients, APP expression 
would elevate and thus cause an early occurrence of AD type symptoms.12,29  
1.9.2 Production of Aβ 
It is noted that both healthy individuals and patients with AD produce Aβ. It is a matter of fact that 
in healthy individuals, the generated Aβ gets cleared by various hydrolyzing enzymes.31 In AD 
patients, the Aβ clearance mechanism is hindered by various unknown mechanisms which cause 
an imbalance in the generation and removal of this protein.27 It is interesting to know, how Aβ gets 
cleared out of the body. More explanation will be discussed in the next section. 
Aβ is known to be present in extracellular fluids, including plasma and CSF (cerebrospinal fluid).54  
Production of Aβ is an example of regulated intramembrane proteolysis (RIP) of APP.15,55,56 RIP 
is a cascade of events in which the ectodomains of the proteins (present on the surface of the 
membrane—in the case of AD, this surface protein is APP) is first cleaved by protease enzyme; 
which are present on the membrane itself, also known as secretases, keeping the trans-membrane 




by another membrane-anchored enzyme to release small hydrophobic peptides into extracellular 
space and endodomains into cytoplasm respectively. (Fig.1-11). 
APP
 secretase cleavage site
secretase cleavage site 
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Similar to the proteolysis explained above, three proteases, namely α- secretase, β- secretase and 
γ-secretase act on APP (surface protein), resulting in either production of neurotoxic Aβ1-40/42 
peptides or soluble and non-toxic peptides of shorter amino acid sequence (Fig.1-12).57,58 A brief 
summary about these enzymes is given below:  
 
Figure 1-12: Structure of APP along with sites of proteolysis by β and γ secretases 
 
1.9.2.1 α- secretase: This enzyme belongs to A disintegrin and metalloprotease (ADAM) family 
of zinc metalloproteases. There are around 21 different enzymes that belong to the ADAM class. 
The α- secretase can be categorized into ADAM9, ADAM10 or ADAM17/TACE.59 ADAM 
belongs to type-1 transmembrane proteinases. ADAM-9 is known to increase the basal and protein 
kinase c-dependent APPsα release, while ADAM-17 is involved in the cleavage of pro-TNF-α; 
which is a type-1 membrane glycoprotein. The cleavage of APP by α-secretase between amino 
acid 687 and 688 (Fig. 1-13) of APP results in the generation of sAPPα (which is supposed to have 




substrate for γ-secretase which results in the formation of non-toxic p3 (3kDa peptide) and AICD 
(Fig. 1-11). Thus, we can say that the metabolic pathway of α- secretase follows the non-
amyloidogenic pathway. It has also been hypothesized that over-expression/ stimulation of α- 
secretase should prevent the proliferation and aggregation of Aβs to from Aβ oligomers and 
fibrils.57  
1.9.2.2 β-secretase: It is an aspartyl protease enzyme, also known as β-site APP cleaving enzyme 
or BACE.60 It is responsible for cleaving ectodomain part of APP to release sAPPβ, (soluble APP) 
into extracellular fluids, similar to α-secretase but, cleaving sites are different from α-secretase. 
The β secretase cleaves between amino acid 671 and 672 of APP (Fig. 1-13) resulting in the 
formation of sAPPβ, which does not have any neuroprotective or neurotrophic properties. The 
CT99 fragment is generated after the initial processing of APP by β secretase, which then becomes  
a substrate for another cleavage enzyme known as γ-secretase, to produce Aβ fragments and AICD.  
Fragments of the Aβ produced after the final cleavage of CT99 by γ-secretase tends to aggregate 
with other Aβ fragments to form oligomers and then Aβ fibrils. Hence, the cleavage process carried 
out by β secretase is considered as the amyloidogenic pathway.60,61  
1.9.2.3 γ-secretase: This enzyme also belongs to the class of aspartyl protease, and contains four 
different domains: Presenilin-1 (PS1) or (PS-2), nicastrin, APH1, and PEN2, and is known to carry 
out cleavage of its substrates at different sites (γ, ε, and ζ cleavage).62 After the processing of APP 
by the BACE-1 enzyme, γ-secretase can cleave CT99 at various cleaving sites and can produce 
Aβ of different amino acid chains (Fig.1- 13). The γ cleavage can generate Aβ as Aβ1-38, Aβ1-40 or 
Aβ1-42. The ζ- cleavage by γ-secretase produces Aβ1-46, while ε cleavage produces Aβ as Aβ1-49 





Figure 1-13: Summary of action of α, β and γ secretase on APP sequence 
 
1.9.3 Clearance mechanism of Aβ 
 
It is essential for the body to disintegrate the Aβ so that normal physiological functions of the brain 
could be preserved. Elevated levels of Aβ in the brain; in synapse mainly, can impact the excitatory 
transmission and can hinder neuronal hyperactivity.27 Certain protease enzyme such as neprilysin, 
insulin degrading enzyme- belonging to the class of thiol metalloendopeptidases, endothelin 
converting enzyme, angiotensin converting enzyme and matrix metalloprotease (MMP9) are all 
capable of breaking Aβ into smaller peptides.65 For example, in the case of MMP9, Aβ can be 
divided into various C-terminal Aβ fragments such as Aβ1-16, Aβ 1-20, Aβ1-23, Aβ1-30, Aβ1-33, Aβ1-
34.







1.9.4 Aβ induced toxicity  
 
As discussed previously, Aβ peptide is produced from the cleavage of APP by various secretase 
enzymes. APP or amyloid precursor protein is a surface enzyme expected to be responsible for 
cellular adhesion between neurons and is believed to have neurotrophic as well as neuroprotective 
properties.66,67. After a certain interval of time, this surface protein is subjected to replacement, 
and this is done by using various secretase enzymes. One of the cleaved products of APP is Aβ. 
The Aβ peptide produced usually undergoes clearance, but, in the case of AD, this protein tends 
to aggregate and forms Aβ fibrils, which are the main constituents of senile plaque.56. However, 
before Aβ aggregates to form a stable, non-soluble fibril structure, the soluble forms of Aβ are 
known to be highly toxic to most of the biological processes.31,56. The Aβ monomers, dimers and 
oligomers come under this category of being soluble and extremely toxic to the normal biological 
processes. It has been observed that Aβ oligomers are the most toxic species among other forms49. 
The Aβ mediated toxicity can be classified into five main categories as below (Fig. 1-14):31,68:  
 Aβ mediated mitochondrial dysfunction  
 Aβ mediated oxidative stress 
 Aβ mediated synaptic dysfunction  
 Aβ mediated changes in the membrane permeability 






Figure 1-14: Aβ induced mitochondrial dysfunction and oxidative stress  
 
1.9.4.1 Aβ mediated Oxidative stress 
 
Aβ is known to have some metal binding properties. Free metal ions such as Cu2+ and Fe3+  are 
known to form  Aβ-metal chelate complexes.69,70 The ability of the Aβ to bind to these metal ions 
can be explained by the presence of histidine (His6, His 13 and His14) and tyrosine (Tyr10) in the 
molecular structure of Aβ. These amino acid residues are known as the metal binding site, 
especially for Cu2+. The nitrogen atom of the indole ring in histidine and oxygen of the hydroxyl 
group in the tyrosine molecule can provide necessary electrons to the metal ions so that metal ion 
can chelate with Aβ. This metal-Aβ chelate constitutes the base for the reduction of metals by the 




molecular oxygen to generate superoxide anion. These superoxide ions then produce hydrogen 
peroxide by accepting protons (in AD, the pH of brain fluid is slightly acidic). Hydrogen peroxide 
further reacts with reduced metal ions to form hydroxyl radical by Fenton reaction. Superoxide 
ions can also react with hydrogen peroxide to generate hydroxyl ions via Haber-Weiss reaction. It 
should be noted that all these reactions take place due to the generation of reduced form of metal 
chelated to Aβ.  The overall redox reaction by which the metal reduction occurs can be explained 
as follows69–71:  
Aβ Met(S) + Cu2+                                 Aβ Met (S+) + Cu1+ 
Cu1+ + O2                                    Cu2+ + O2.- 
O2.- + O2.- + 2H+                                H2O2  + O2  
Cu1+ + H2O2                                 Cu2+ + OH. + OH-   {Fenton Reaction} 
O2.- + H2O2                                                  OH. + OH- + O2 {Haber- Weiss reaction} 
The Aβ- metal- radical form is capable of abstracting protons from the neighboring proteins and 
lipids and thus causing lipid peroxidation. Also, metal chelated Aβ is susceptible for accelerated 
aggregation as compared to the metal free Aβ.70  
1.9.4.2 Aβ mediated mitochondrial dysfunction  
 
Aβ mediated mitochondrial dysfunction can be proceeded by two major ways (Fig. 1-14). These 
two major pathways are;  
 Changes in the membrane permeability of cells- this phenomenon is caused by the 
formation of Aβ pores on the surface of the cells. These pores can carry Ca2+ ions freely 




the cytosol and thus, mediates the Ca2+ induced mitochondrial dysfunction.  Ca2+ enters the 
mitochondria and causes disruption of electron transport chain (ETC), oxygen 
consumption, the membrane potential of mitochondrial membranes. An interruption in the 
ETC soon causes the release of cytochrome C which will initiate a cascade of reactions and 
causes apoptosis of the cells via caspase mechanism.72–76  
 The presence of interneuronal Aβ: It is evident from various microscopic studies that Aβ 
can penetrate the cell wall and can accumulate within different cell organelles of the 
neurons; mitochondria in particular. Aβ aggregates have been present the mitochondria of 
the AD patients as well as AD mouse models. It has been hypothesized that Aβ when 
present in mitochondria can chelate to the metal ions such as copper and iron. These metal 
ions are required for proper functioning of ETC, and thus, the presence of Aβ can hinder 
ETC efficiency and thus causes cells to die off because of reduced production of ATP in 
the neuronal cells.72–74  
1.9.4.3 Aβ mediated changes in the membrane permeability 
 
As it has already been discussed previously, that Aβ causes the change in the membrane 
permeability. This occurs due to insertion of Aβ peptides inside the cell wall of the neurons and 
causes an increase in the permeability of the cell wall by forming Aβ channel pores. A soluble 
form of Aβ i.e. monomers, dimers and oligomers are known to interact with the cholesterol 
molecules which are present on the surface of the cell walls. This interaction between Aβ and 
cholesterol causes Aβ to get inserted into the cell wall without compromising the elasticity of  the 
cell wall. The cell wall with Aβ channel pores is highly permeable to the Ca2+, and this results in 
elevated Ca2+ levels within the neuronal cells and thus results in various Ca2+ regulated downstream 




1.9.4.4 Aβ mediated synaptic dysfunction  
 
AD is considered to be a disorder of synaptic dysfunction. In mild AD, hippocampal synapse 
begins to collapse, and a decrease in synaptophysin (a presynaptic vesicle protein) is observed. All 
these events have been linked to the effect of Aβ’s presence at the synaptic cleft region. Soluble 
forms of Aβ: mostly oligomers, is known to impair synaptic plasticity by disturbing the balance 
between long-term potentiation (LTP) and long-term depression (LTD). Both LTP and LTD are 
related to the activity of AMPA (2-amino-3-(3-hyrdoxy-5-methylisoxazol-4-yl)-propionic acid) 
receptors. LTP is caused by the increased activity of AMPA receptors in the postsynaptic 
membrane, while, AMPARs constant removal and decreased function is related to cause LTD. 
This observation becomes a hypothesis that AMPARs number and function exhibit a significant 
role in AD pathology.12,66,79 It was observed that Aβ oligomers are known to have an endocytotic 
effect when present near AMPARs which leads to LTD. With NMDA (N-methyl-D-aspartate) 
receptors, the effect of Aβ is different. The NMDA receptors, similar to AMPA receptors, belong 
to the category of glutamate receptors, but the mechanism by which Aβ modifies the activity of 
NMDA receptors is completely different. It is believed that Aβ causes excessive activation of the 
NMDA receptors and this leads to excessive accumulation of Ca2+ within the neurons which leads 
to neuronal excitotoxicity. This observation was proved when a solution of Aβ40 was given to 
hippocampal cells causing cell death of the hippocampal cell lines. Neuroprotection was observed 
in the presence of memantine (NMDA receptor antagonist) in the cell cultures. This observation 
supported the idea that NMDA receptor plays a vital role in Aβ induced neurotoxicity.22,80–83 The 
Aβ is also known to impair the activity of acetylcholine receptors (AChRs) by either inhibiting the 




A summary of the mechanism of the Aβ hypothesis can be represented in a flow diagram as follows 
(Fig. 1-15).   
 
Figure 1-15: Summary of the mechanism of Aβ hypothesis 
1.9.5 Approaches for Targeting Amyloid- β  
 
There are various methods which can be considered while targeting the Aβ cascade as potential 
therapeutics for AD management. The primary target is based on using small molecules as Aβ 
aggregation inhibitors. Though this sounds one of the easiest methods; this might not be entirely 
application to a wide variety of patients. It has been observed that by the time patients are 
diagnosed with AD, the Aβ load is high. As a result, this particular type of approach might not 
apply to patients with advanced AD symptoms. Other targets have been characterized by the Aβ 




reducing the Aβ load in the brain. Ideally, if potential therapeutic could reduce the Aβ load in the 
brain of the patient and initiate neurogenesis, that drug could be able to reverse the 
pathophysiology of AD. Despite rigorous efforts,   investment in time and s and money,  no new 
anti-AD drug  has reached the market yet. Some AD targets are as follows:   
1.9.5.1 β-secretase inhibitors: BACE-1 inhibitors work on the principle of inhibiting the 
production of Aβ production by inhibiting the activity of the enzyme responsible for the production 
of Aβ from APP. Preventing Aβ production in the brain, though sounds an ideal option, is 
challenging because of the various reasons such as (1) inability of most of the BACE-1 inhibitors 
to penetrate the blood-brain barrier (BBB); (2) Therapeutic considerations for its safety, efficacy, 
and tolerability; (3) Prediction of mechanism-based toxicity/ side effects..84–89 Some small 
molecules have made progress in the discovery ladder:  
 Verubecestat: developed by Merck & Co. is currently in phase-III clinical trials (Fig. 1-
16). 
 
Figure 1-16: Molecular structure of Verubecestat 
Verubecestat is a potent BACE-1 inhibitor with an IC50 of 13nM for BACC-1. This drug 
is known to bind to the aspartate amino acid residues in the active site of BACE-1 and 
prevents the activity of the β-secretase enzyme. This drug, in early clinical studies, is 




single administration of this drug via oral route has been observed to reduce the load of Aβ 
in CSF by 92%.89,90 
 AZD3293- developed conjointly by AstraZeneca and Eli Lilly (Fig. 1-17) is currently 
undergoing Phase-III clinical trials and targets BACE-1 for preventing Aβ production.89,90 
Currently in Phase-III clinical trials. 
     
Figure 1-17: Molecular structure of AZD3293 
 CNP520 developed by Novartis and Amgen pharmaceuticals and JNJ-54861911 developed 
by Johnson and Johnson are some of the other drugs which are currently under 
investigation for Phase-II/III trials.89,90  
1.9.5.2 Aβ aggregation inhibitors:  Small molecules are specifically designed to prevent the 
formation of Aβ oligomeric aggregates, which are insoluble and toxic in nature. Some small 
molecules have metal chelating properties which can further enhance their efficacy.91,92.  
According to Atwood and coworkers, Cu2+ and Zn2+ ions are associated with the aggregation of 
Aβ, and administration of metal chelator molecule which can cross the blood-brain barrier can 
drastically reduce the aggregation of Aβ.69,71  
1.9.5.3 Aβ Immunotherapy: Immunotherapy involves the administration of peripheral 
antibodies, for which aggregated Aβ1-42 acts as an antigen and are effective in reducing the 
deposition of Aβ aggregation. It also helps in suppressing the amyloid-associated pathology which 




improvement in synaptic plasticity was observed.93–96 The table (Table 1) below provides a list of 
antibody therapies aimed at scavenging various Aβ aggregates  90:  
S. No.  Antibody Aβ  Target  status company 
1 Crenezumab Oligomers Phase-III Genentech/ 
Roche 






3 Solanezumab Soluble monomers Failed Phase-
III 
Eli Lilly 
4 Gentenerumab Plaques Failed Phase-
III 
Roche 
5 Aducanumab Plaques and oligomers Phase-III Biogen 
 










Chapter 2. Hypothesis and Design Rationale 
2.1 Proposal 
 
Figure 2-1: Cholinesterase inhibitors (1–4) with a fused tricyclic ring template 
 
The fused tricyclic ring is a common chemical feature present in a number of cholinesterase 
inhibitors (Fig 2.1). The β-carboline (compound 1) is a known cholinesterase inhibitor whereas 
the 1,2,3,4-tetrahydroacridine containing tacrine (2) was the first drug marketed to treat 
Alzheimer’s disease9. Another natural product mackinazolinone (compound 3, Fig 2.1) based 
derivatives and the phenothiazine (4) derivatives are known to exhibit dual cholinesterase 
inhibition91. These compounds have smaller molecular volumes (range ~ 139.9–153.5 Å3) and 
bind to the catalytic sites of both AChE (monovalent inhibitors) and BuChE enzymes. The 
complexity of AD is highlighted by the fact that addressing only the cholinergic hypothesis using 
cholinesterase inhibitors can provide only symptomatic relief and is not a long-term solution2,12. 
These findings led us to design novel fused tricyclics capable of exhibiting multi-targeting 
potential. The objective was to develop small molecules to inhibit (i) the cholinesterase enzymes; 
(ii) prevent Aβ aggregation and (iii) exhibit antioxidant properties. A literature search led us to a 
novel fused tricyclic ring template pyrazino[1,2-a]indol-1(2H)-one (Fig 2-2). Initial modeling 
studies indicated that this novel tricyclic ring was able to bind in the catalytic site of AChE enzyme 
(Figure 2.3, panel A). Our goal was to modify the structure of this template to provide bivalent 




aggregation97,98. Based on this observation, we decided to pursue 3-phenylpyrazino[1,2-a]indol-
1(2H)-one  (abbreviated as PPI in this thesis) derivatives (Fig 2-2) as the molecular docking 
experiment of PPI in AChE shows that the core fused tricyclic pyrazino[1,2-a]indol-1(2H)-one 
ring was interacting with the catalytic site of AChE (Fig 2-3, panel B) whereas the C3 phenyl was 
oriented in the PAS of AChE suggesting its potential exhibit bivalent inhibition. In addition, we 
anticipated that the PPI could stabilize the dimer assembly and prevent Aβ self-assembly and 
aggregation into higher order structures. In this regard, the molecular docking study of PPI in the 
Aβ40 dimer model suggests that the molecular structure of PPI and its derivatives are capable of 
preventing the Aβ aggregation by interacting with the hydrophobic regions of the Aβ protein such 
as KLVFFA region. (Fig 2.4) represents the molecular docking studies of PPI with the dimer model 
of Aβ40. 
 
Figure 2-2: The chemical structure of proposed novel fused tricyclic ring system 3-




          
(A)                                                                                            (B) 
                                                                                
                         (C )                                                                                    (D) 
 
Figure 2-3: Binding modes of pyrazino[1,2-a]indol-1(2H)-one (panel A)  and 3-






    
(A)                                                                                            (B)  
Figure 2-4: Binding mode of 3-phenylpyrazino[1,2-a]indol-1(2H)-one (Panel A and B) in the 
Aβ40 dimer assembly. 
 
2.1.1  3-Phenylpyrazino[1,2-a]indol-1(2H)-one (PPI) 
 
The pyrazino[1,2-a]indole derivatives are known to exhibit a number of biological activities  
ranging from serotonin antagonists, thrombolytic, CNS depressants, anxiolytics, antihistamines, 
anticonvulsants, protein kinase inhibitors, antifungal and as antibacterial agents.99 Various 
substituted Pyrazino[1,2-a] indoles have known biological activities and have been investigated 
for its actions ranging from serotonin antagonists, thrombolytic, CNS depressants and, anxiolytics 
for which the BBB penetration is essential99. 
We aim to incorporate C3 pharmacophores capable of providing anti-Aβ and antioxidant 




C3 position. Previous studies from the Nekkar Rao lab has shown that the presence of a 3,4-
dimethoxybenzyl substituent in tacrine and quinazoline-based derivatives provided dual 
cholinesterase inhibition and anti-Aβ aggregation properties.100 Other proposed C3 substituents 
include adding phenolic groups that possess antioxidant properties such as 3-methoxy-4-
hydroxyphenyl and 4-hydroxy-3-methoxyphenyl substituents at the C3 position. These 
substituents are known to be in the natural antioxidant curcumin.101 
 













 AD is a complex disease. The current pharmacotherapy options based on cholinesterase 
inhibition is inadequate. The amyloid cascade hypothesis shows that aggregation of Aβ is a major 
event known to promote neurotoxicity, mitochondrial dysfunction, oxidative stress, 
neurodegeneration and cognitive decline. Our proposal has identified a novel fused tricyclic 3-
phenylpyrazino[1,2-a]indol-1(2H)-ones (PPI) as a suitable system to incorporate multi-targeting 
activity such as cholinesterase and Aβ aggregation inhibition, and antioxidant activity. A library 
of PPI derivatives will be synthesized and evaluated by structure-activity relationship (SAR) 
studies to understand the structural requirements for multi-targeting activity. The planned 
experiments include compound library synthesis, their characterization, in vitro studies using 
human AChE and BuChE enzymes, Aβ aggregation kinetics, transmission electron microscopy 
(TEM) experiments and molecular docking studies. These results would provide evidence on the 












Chapter 3. Methodology  
3.1 Introduction  
This chapter describes (i) the synthetic chemistry methods used to prepare PPI derivatives and the 
reaction mechanisms involved; and (ii) the principles of biological assay methods used including 
cholinesterase inhibition, Aβ40/Aβ42 aggregation kinetics studies, transmission electron 
microscopy, molecular docking and antioxidant assays.   
3.2 Preparation of PPI derivatives  
The synthetic summary to prepare the PPIs library is shown in Scheme 3.1. It was commenced by 
using commercially available substituted or unsubstituted indole-2-carboxylic acids (1a-c, Scheme 
3.1). Esterification of these indole carboxylic acids under mild conditions provided ethyl indole-
2-carboxylates (2a-c) in excellent yields (yield 75-80%). Coupling of these indole carboxylates 
with substituted or unsubstituted 2-bromoacetophenones (3a-m) provided ethyl 1-(2-oxo-2-
phenylethyl)-1H-indole-2-carboxylates(4a-n) with yields ranging from 14-45%. Cyclization of 
4a-n coupled product gave us the targeted compounds (5a-n) in excellent yields 65-75% as shown 


















Scheme 3-1: General scheme to synthesize PPI derivatives 5a-o. Reagents and conditions– (a) 
EtOH, Conc. H2SO4, Reflux, 78°C, 24h; (b) Substituted 2-bromoacetophenone (1.2 eq), Cs2CO3 
(2 eq), KI (catalytic qty.), ACN, reflux at 70°C for 24h ; (c) CH3COONH4 (10 eq.), BuOH: 







3.2.1 Preparation of ethyl indole-2-carboxylates 2a-c 
 
 
Scheme 3-2: Synthesis of ethyl indole-2-carboxylates (2a-c) 
 
Indole-2-carboxylic acids 1a-c were subjected to an esterification using ethanol in the presence of 
catalytic amounts of conc. H2SO4 under reflux. The product was obtained in excellent yields 





Figure 3-1: Fisher esterification of indole-2-carboxylic acids. 
3.2.2. Preparation of ethyl 1-(2-oxo-2-phenylethyl)-1H-indole-2-carboxylates (4a-n) 
 
 





Ethyl-1-(2-oxo-2phenylehyl)-1H-indole-2-carboxylates (4a-n) were synthesized by coupling 
ethyl indole-2-carboxylates (2a-c) with 2-bromoacetophenones (3a-m) in the presence of CS2CO3 
and KI as a catalyst under reflux as shown in Scheme 3-3. This reaction provided moderate to good 
yields (14-45%).   
This coupling reaction follows SN2 type mechanism and can be written as follows: 
 









Scheme  3-4: Synthesis of 3-phenylpyrazino[1,2-a]indo-1-(2H)-ones 
This is the last step in the preparation of target PPI compounds. We started by adding 
CH3COONH4 to ethyl 1-(2-oxo-2-phenylehyl)-1H-indole-2-carboxylates (4a-n) in n-BuOH and 
AcOH (4:1 ratio) in a pressure vial. The reaction mixture was then subjected to react under high 
temperature (150 0C using an oil bath) to afford the target compounds 5a-n in good yields (65-






Figure 3-3: The proposed intramolecular cyclization of ethyl-1-(2-oxo-2-phenylehyl)-1H-
indole-2-carboxylate to afford 3-phenylpyrazino[1,2-a]indo-1-(2H)-one 
3.2.3.1 Preparation of substituted 2-bromo acetophenones (3a-m) 
 
 
Scheme  0-5: Synthesis of 2-bromoacetophenones 




All the 2-bromoacetophenones (3a-m) utilized in the synthesis were prepared in-house by 
brominating substituted acetophenones with CuBr2 as the source of bromine (Scheme 3-5). The 
reaction was initiating by activating CuBr2 in EtOAc under heating after which substituted 
acetophenones was added to the reaction mixture, and the reaction mixture was stirred under reflux 
conditions to afford 2-bromoacetophenones (yield range 70-90%). CuBr2 mediated bromination 
can be explained by the following mechanism102: 
 









O-Tert-butyldimethylsilyl (O-TBDMS) protection of 2-bromo-hydroxyacetophenones 
 
Scheme  3-6:  OTBDMS protection of hydroxy acetophenone 
 
To prevent the reactivity of hydroxy acetophenone during their coupling with the indole esters (2a-
c, Scheme 3-3), the phenolic groups were protected using the TBDMSCl reagent as shown in 
Scheme 3-1. The reaction of hydroxy acetophenone with TBDMSCl in the presence of base 
triethylamine at r.t. Provided OTBDMS-protected Bromo acetophenones in good yields (~50%).  
The mechanism of which is as given in Fig 3.5.  
  
 





Deprotection of the OH group was done in the second step itself when the reaction mixture was 
washed with 1M HCl solution before washing it with conc brine solution. Additional washing with 
the HCl solution helped to remove the protecting group, giving the free –OH.   
3.3. Biological assay methods  
3.3.1 Cholinesterase (ChE) enzyme inhibition assays   
 
In 1961, Ellman described an easy and rapid colorimetric method for defining the 
anticholinesterase activity of small organic molecules103,104. In this approach, sulfur analogs of 
ACh (ATCh- thioacetylcholine) and BuCh (BuTCh- thiol butyrylcholine) were used as substrates. 
In the absence of ChE inhibitors, these sulfur analogs were hydrolyzed by ChE to form thiocholine 
and respective acids (i.e. acetic acid and butyric acid). The thio-choline generated reacts with on 
dithiobis-(2-nitrobenzoic acid) (DTNB), to produce 2-nitro-5-thiobenzoic acid (NTB). The NTB 
is a yellow chromophore (Fig.3-6), which can be detected at a wavelength ranging from 405 nm 
to 412 nm. In the presence of an inhibitor, the generation of thiocholine by the hydrolysis of ATCh/ 
BuTCh gets reduced which can be quantified to determine ChE inhibition (IC50 values). Reference 
agents such as donapezil and rivastigmine were included for comparison of inhibitory potency of 






Figure 3-6: Principle of Ellman assay to determine ChE inhibition 
 
3.3.2. Aβ aggregation inhibition assay 
 
This method is based on the principle that a change in the intensity of the fluorescence is observed 
when fluorescent dyes such as thioflavin T (ThT) bind to the β-sheet structure of Aβ which can be 
monitored at 450 nm (Excitation wavelength) and 490 nm (emission 
wavelength)respectively105,106. A linear correlation between the relative fluorescence unit (RFU) 
and the aggregation process can be made106. Molecules which can inhibit the aggregation of Aβ in 
solution when ThT is present will result in lower relative fluorescence units (RFU’s) and molecules 
which cannot inhibit the aggregation of Aβ or, which can induce the aggregation of Aβ will have 
a higher RFU. Hence, a linear relationship can be observed by monitoring fluorescence — Higher 




was conducted using Aβ40/42. The known Aβ aggregation inhibitor orange G was used as a 
reference compound.  
 3.3.3. Molecular modeling   
 
Molecular docking studies of PPI derivatives were performed using Discovery Studio (DS) 
Structure-Based-Design, version 4.0 (BIOVIA, San Diego, U.S.A). For performing the docking 
studies, X-ray crystal structure of AChE (PDB:4EY7), BuChE (PDB: 2XQJ), Aβ40 (PDB:2LMN) 
and Aβ42 (2NAO) were obtained from RCSB protein data bank. To the enzyme structure, 
hydrogens were added.  Test compounds were built in 3D using Build Fragment tool, and energy 
minimization were performed for 1000 iterations using steepest descent and conjugate gradient 
minimizations respectively. The CDOCKER algorithm in the receptor-ligand interactions was 
used to dock the molecules with appropriate enzymes after defining a 15 Å sphere radius within 
the enzyme which covers all the active site amino acids. CHARMm force field was used for the 
docking studies. The quality of ligand-enzyme complex was evaluated based on CDOCKER 
Interaction energy and CDOCKER energy in kcal/mol. Also, polar and nonpolar interactions were 
visualized to assess the critical interactions involved in compound binding with the respective 
enzyme/ protein.    
3.3.4. Anti-oxidant activity 
 
The ability of PPI derivatives to scavenge and neutralize free radicals was determined by using a 
stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH)107,108. DPPH radical in solution appears 
to be purple in color with strong absorbance at 517nm. The neutralization of this radical by an 
antioxidant source results in the formation of a stable DPPH species which have a very weak 





Figure 3-7: Scavenging of DPPH radical to form stable DPPH molecule. 
 
3.3.5: Transmission electron microscopy (TEM) 
 
To assess the morphology of amyloid beta protein after the incubation of the protein with or 
without the presence of synthesized compounds, transmission electron microscopy (TEM) is used. 
TEM imaging assay results were used to support the results obtained from the Aβ aggregation 
kinetics assay. Images obtained from TEM can be used to explain the mechanism of Aβ 
aggregation by comparing the images of Aβ alone as well as the morphology of the Aβ observed 










Chapter 4. Results and Discussion  
4.1 Introduction 
As discussed in Chapter 2, the primary aim of this research project was to synthesize a compound 
library based on PPI template, acquire SAR data and assess its anti-AD potential.  
In this segment, we will discuss the observed biological activities of the compound library toward 
ChE enzymes, amyloid protein Aβ40/42 aggregation properties and their antioxidant properties. We 
will also support our results with TEM experiments (for supporting anti-Aβ40/42 aggregation 
properties) as well as in silico molecular docking studies to understand the binding interactions 
(for ChE inhibition properties and anti- Aβ40/42 aggregation properties). Best molecular candidates 
will be those compounds which can exhibit ChE inhibition properties, inhibit aggregation of Aβ 
and exhibit antioxidant properties.  
4.1.1: Cholinesterase (ChE) enzyme inhibition assays: The ability of the synthesized PPI 
compound library (5a-q) to exhibit cholinesterase inhibition activity was the first and foremost 
biological evaluation performed. Known ChE inhibitors donepezil and rivastigmine were used as 
reference agents. We expect the compounds based on PPI template to show dual AChE/ BuChE 
inhibition properties. Our modeling studies suggest that PPI derivatives would be more specific to 
inhibit AChE than BuChE due to the difference in the active size of these enzymes. This difference 
has been explained previously in Section: 1.8.3.1 (Chapter 1). 
The anti-AChE/ BuChE data is shown in Table 4-1. The results have been presented as IC50 values 
which define the amount of compound required to inhibit the activity of the compound by 50%112. 
Other parameters such as partition coefficient (clogP), selectivity index, and molecular volume 














1. 5a H H 8.73 ± 0.17 
 
19.81 ± 0.99 3.69 189.67 
2. 5b H 4-OH 7.7 ± 0.74 
 
19.82 ± 1.7 3.14 207.17 
3. 5c H 4-OMe 7.53 ± 0.32 18.40 ± 0.46 3.67 216.08 
4. 5d H 3,4-diOMe 7.47 ± 0.54 15.18 ± 0.62 3.39 243.52 
5. 5e H 3-OMe 7.56 ± 0.79 > 50 3.67 218.49 
6. 5f H 3,4,5-triOMe 7.21 ± 0.53 17.98 ± 0.70 3.01 294.97 
7. 5g H 3-OH 7.01±0.31 19.59± 0.2 3.14 199.28 
8. 5h H 2-OMe 7.30 ± 0.41 1.9 ± 0.03 3.11 220.2 
9. 5i H 2,4-diOMe 7.67 ±0.72 21.42 ± 1.1 3.18 244.21 
10. 5j H 2.5-diOMe 7.91 ± 0.72 17.07 ± 0.07 3.18 243.52 
11. 5k H 4-OH, 3-OMe 8.7 ± 0.42 
 
>50 2.97 231.18 
12. 5l H 3-OH, 4-OMe 7.60 ± 0.97 >50 2.97 232.89 
13. 5m 9-OMe H 7.18±0.61 >50 3.65 216.43 
14. 5n                                    8-OMe H 6.34±0.27 >50 3.67 218.14 
15. Donepezil 
 
  0.003 ± 0.001 3.6 ± 0.7 4.59 321.7 





Table 4-1: Compiled data for compounds 5a-n (a) IC50 data for against AChE/ BuChE, (b) CLogP 
values (c) Selectivity index of 5a-n towards AChE against BuChE (d) Molecular volume of the 
compounds 5a-n.  
IC50 values of the compounds presented in the table are the mean of three separate experiments (n 
= 3), and the standard deviation is represented as (± values) from its average value. ClogP values 
were calculated using ChemDraw Professional software from CambridgeSoft company. Molecular 
volume (MV) was calculated using Discovery Studio program from BIOVIA Inc (San Diego, CA).  
 
 
Figure 4-1: Bar graph of AChE and BuChE inhibition profile of PPI derivatives 5a-n. Results are 








IC50 data comparison 











The OMe substituted compounds became the largest subset of the substitutions made at the C3 
phenyl moiety as well as at position C8 and C9 of the indole moiety in the PPI ring system. Under 
this subset, seven compounds were synthesized, and their activity was compared. In the C3 phenyl 
substituted series of compounds, it was interesting to note that almost all of them showed similar  
activity (by comparing the IC50 values) toward AChE. The IC50 range was between 7 to 8 μM 
(Table 4-1, Figure 4-1) which were similar to that of rivastigmine (IC50 ~8.5 μM). This similarity 
in the activities of these compounds towards AChE can be explained by the fact that, the volume 
of AChE active site is narrow and small (~302 Å3), while the molecular volume of the compounds 
lies in the range of (189.69Å3 to 294.97Å3 ). Thus, C3 methoxy-substituted compounds 5c, 5d, 5e, 
5f, 5h, 5i, 5j exhibited a similar range of activity and were not potent inhibitors of AChE compared 
to donepezil (AChE IC50 = 3nM, Table 1). In contrast, much weaker inhibitory activity was   
observed when the compounds were tested against BuChE (Table 4-1, Figure 4-1) and most of the 
compounds were less potent compared to their AChE inhibition profile. In general, the inhibition 
activity ranged from 15-21 μM with few compounds not exhibiting any inhibition at the maximum 
concentration tested (IC50 < 50 μM, Table 1, Fig. 4-1). In the BuChE SAR, it appears that the C3 
phenyl substituents contributed in enhancing BuChE inhibitory potency with the unsubstituted C3 
phenyl containing compound 5a (Table 1) exhibiting weak BuChE inhibition (IC50~ 20 μM) 
whereas increasing the size this ring led to gradual improvements in BuChE inhibitory potency 
with compound 5c (R1 = 4-methoxyphenyl; BuChE IC50 = 18.4 μM) and 5d (R1 = 3,4-
dimethoxyphenyl; BuChE IC50 = 15.1 μM) exhibiting better inhibition (Table 1).   
The addition of a C3 3,4,5-trimethoxyphenyl ring (compound 5f) did not further improve the 
activity toward BuChE (IC50~ 18 μM). Interestingly, compound 5h (3-(2-




series (BuChE IC50 = 1.90 μM, Table 4.1) and was almost 1.8-fold more potent compared to the 
reference agent donepezil (BuChE IC50 = 3.60 μM). At this point, we are not able to explain the 
reason for this observation. It is plausible that the intramolecular interaction with the OMe and NH 
of pyrazinone (Fig. 4-2) can potentially lock compound 5h in a favorable conformation within the 
BuChE active site. Molecular docking of 5h in BuChE is discussed later in this chapter.   
 
                         
Figure 4-2: Proposed intramolecular interaction of ortho-OMe substituent with pyrazinone                                     
 
The corresponding regioisomers 5n and 5m which had substituents at either C8 or C9 position (on 
the indole ring) that exhibited similar AChE inhibition properties as C3 phenyl substituted 
compounds with IC50 values of  7.18 μM and 6.34 μM respectively for compounds 5n and 5m.   
Interestingly, both of these compounds were found to be inactive against BuChE (IC50 > 50 μM, 
Table 4.1).  
To incorporate antioxidant properties, we included phenolic groups at the C3 position (compounds 
5b and 5g, Table 4.1).  These compounds were able to exhibit dual ChE exhibition and did not 
show any significant difference compared to the unsubstituted compound 5a (5b: IC50 AChE= 7.7 




contrast, incorporation of another antioxidant pharmacophore viz: 4-hydroxy-3-methoxyphenyl or 
4-methoxy-3-hydroxyphenyl substituents at the C3 position provided selective inhibition of AChE 
in compounds 5k and 5l (AChE IC50 ~ 7.7 μM; BuChE IC50 < 50 μM). 
 
 
4.1.2: Molecular docking of 5m and 5d using AChE enzyme 
 
The binding interactions of best candidates with ChE inhibition was investigated by molecular 
docking experiments. The most potent AChE inhibitor 5m (IC50 ~ 6.3 μM) was investigated using 
the known x-ray crystal structure of human AChE enzyme (Figure 4-3). It was observed that the 
compound 5m was mostly interacting with the amino acids present in the PAS- Trp286, Tyr124, 
Asp74, andTyr341. Strong hydrogen bonding was found between the C1 carbonyl oxygen and the 
–OH of Tyrosine341 amino acid (distance~ 2Å), as well as between NH at 2nd position and 
carbonyl carbon of the Asp74 (distance ~2.9Å). Even though it was present very close (distance~ 
3.6Å) from to the His447 (part of the catalytic triad), no interactions were observed between the 




    
Figure 4-3: The binding mode of compound 5m in the active site of human AChE enzyme. 
 
Next, we investigated the binding interactions of the dual ChE inhibitor 5d in the active site of 
AChE (Figure 4-4). It was interesting to note the orientation of compound 5d in the active pocket 
of the hAChE enzyme. The tricyclic ring system was found to be away from the catalytic triad 
(distance from His447~ 3.9Å), and no interactions were found between the tricyclic ring and the 
catalytic triad. Rather, the tricyclic ring system was found closer to the acyl pocket (~ 3Å from 
Phe295), PAS (~ 5.5 Å from Tyr124) and the hydrophobic subsite (~4.8Å and 5.2 Å from Trp86 
and Tyr337 respectively). While the C3 diOMe-phenyl ring was found to interact with the Tyr124 
via pi-pi T-shaped interactions (distance ~ 5.2 Å) in the PAS. This study shows that the 3,4-







Figure 4-4: The binding mode of compound 5d in the active site of human AChE enzyme. 
 
Molecular docking of 5h in the active site of BuChE enzyme  
 
Figure 4-5: The binding mode of compound 5h in the active site of human BuChE enzyme. 
 
Mode of interaction of compound 5h with hBuChE (PDB: 1POI) has been depicted in fig. 4-5. It 




the BuChE enzyme and was interacting with the His438 (part of the catalytic triad) via pi-pi-T 
stacking interactions. Compound 5h also targeted the choline binding site (Trp82) via pi-pi-T 
stacking interactions (distance ~ 5.6 Å). Due to the ability of 5h to target both catalytic triads as 
well as choline binding site resulted in its capacity to block the activity of BuChE. 
4.1.3: Conclusions: Our results indicate that majority of the PPI derivatives evaluated exhibit dual 
cholinesterase inhibition with some compounds exhibiting selective AChE inhibition.  Among, the 
compounds synthesized, compounds 5e, 5k, and 5l were identified as selective AChE inhibitors 
with IC50 values ranging from ~7-9 μM. Compound 5h was recognized as the most potent BuChE 
inhibitor (IC50 = 1.9 μM) and was 1.8-fold more potent compared to the reference agent donepezil. 
In this PPI library compound 5h (Fig. 4-6) was identified as the best compound with dual AChE/ 
BuChE inhibition profile ( AChE IC50 =7.3 μM;  BuChE IC50 =1.9 μM). Some of the best 
compounds from the series are highlighted in Fig.4-6. These studies show that PPI derivatives do 
have ChE inhibition properties. However, they exhibit weak inhibition profile compared to 
marketed ChE inhibitors (e.g., donepezil). Nevertheless, the study suggests that PPI template is 
amenable to further SAR optimization.  
                                                                                 
                                5h                                                                                5n                            
             IC50 AChE = 7.3 μM                                                          IC50 AChE = 6.3 μM                                   
             IC50 BuChE = 1.9 μM                                                        IC50 BuChE = >50 μM 




4.2: Amyloid-beta aggregation inhibition studies 
After estimating the anti-ChE activity of synthesized compounds, PPI derivatives 5a-n were 
further evaluated for their ability to inhibit aggregation of Aβ1-40/42 by using ThT based 
fluorescence. The test compounds were tested at three different concentrations of 1, 5 and 25 μM. 
The results are presented as average % inhibition ± s.d. n = 3 for three independent experiments 
and were compared with the known inhibitor orange G.   
 
4.2.1: Activity of PPI derivatives toward Aβ1-40 aggregation  
 












Table 4-2: Aβ1-40 aggregation inhibition activity of PPI derivatives 5a-n. 
 
The results are expressed as average ± SD (n = 3) for three independent experiments. The 
aggregation kinetics assays were carried out using a ThT-based fluorescence assay (excitation = 
440 nm and emission = 490 nm) in the presence of 5 μM of Aβ1-40 in phosphate buffer pH 7.4 at 
37 ºC with shaking over a period of 24 h.  
 
Compounds with OMe substituents at either C3 phenyl or indole ring (5m-o) exhibited good Aβ40 
aggregation inhibition properties (compounds 5c-f, 5h-j, 5m and 5n). Compound 5d with a C3 
3,4-dimethoxyphenyl substituent exhibited superior anti-Aβ40 aggregation property at all the tested 
Compound R R’ % inhibition at 
1 μM 
% inhibition at 
5 μM 
% inhibition at 
25 μM 
5a H H 60.7 62.8 67.4 
5b H 4-OH 41.6 59.3 63.0 
5c H 4-OMe 32.4 42.9 50.9 
5d H 3,4-diOMe 49.9 56.2 83.3 
5e H 3-OMe 41.6 37.5 17.6 
5f H 3,4,5-triOMe 23.2 43.2 52.9 
5g H 3-OH 7.8 29.8 74.4 
5h H 2-OMe 33.0 40.1 67.7 
5i H 2,4-diOMe 48.7 55.5 71.9 
5j H 2.5-diOMe 42.6 29.2 19.2 
5k H 4-OH, 3-OMe 61.7 53.9 58.4 
5l H 3-OH, 4-OMe 41.1 40.0 42.5 
5m 9-OMe H P.A. 14.5 32.7 
5n 8-OMe H 1.6 13.0 43.4 




concentrations (~ 50%, 56% and 83% inhibition of aggregation at 1, 5 and 25 μM respectively, 
Table 2). The C3 phenyl unsubstituted compound 5a exhibited good aggregation properties at all 
the concentrations. However, there were no significant changes observed in the concentration 
range tested with 60-67% inhibition seen (Table 4-2). Both compounds 5a and 5d exhibited 
superior inhibition at 25 μM (67% and 83% inhibition respectively, Table 4.2) compared to the 
reference agent Orange G (59% inhibition, Table 4-2). Replacing the  C3 3,4-di-OMe-phenyl 
substituent in 5d with a 2,4-di-OMe-phenyl substituent in 5i reduced the anti-Aβ aggregation 
activity compared to 5d, although the compound 5i did exhibit better activity compared orange G 
at 25 μM (71.9% inhibition). Interestingly, the presence of a 2,5-di-OMe-phenyl substituent in 
compound 5j led to a gradual decline in its anti-aggregation activity as the compound 
concentration was increased from 1 to 25 μM (19.2% at 25 μM; Table 4.2). Addition of a C3 3,4,5-
trimethoxyphenyl substituent (compound 5f) provided anti-Aβ aggregation activity (23-53% 
inhibition, Table 4.2). However, it was not as potent as the di-OMe substituted derivatives 5d and 
5i. Mono OMe substitution at the C3 phenyl (compounds 5c and 5e) showed weaker inhibition of 
Aβ aggregation compared to the 2,4-/3,4-di-OMe and 3,4,5-tri-OMe-phenyl substituted 
derivatives. The presence of phenolic groups in compounds 5b (63% inhibition) and 5g (74% 
inhibition) provided better inhibition compared to the corresponding OMe derivatives 5c and 5e 
(Table 4.2).  The presence of OMe substituent at either the C8 or C9 position (indole ring) in 
compounds 5n and 5m exhibited weaker inhibition of Aβ aggregation (33% and 43% inhibition at 
25 μM) about the OMe substituted derivatives at the C3 phenyl ring (Table 4.2). Incorporation of 
both OH and OMe substituents at the C3 phenyl rings (compounds 5k and 5l) led to retention of 
Aβ aggregation inhibition properties with compound 5k exhibiting similar activity (58% inhibition 




best PPI inhibitor 5d is shown in Figure 4.4(b) and is compared with orange G kinetics (Figure 
4.4(a)). In the absence of test compounds, the Aβ40 aggregation kinetic curve follows a sigmoidal 
pattern (represented as 100% control- yellow line, Figure 4.4). This pattern can be divided into 
various phases representing (a) a lag phase (flat line till ~ 10 h mark), (b) growth phase- 
exponential growth in the aggregation of the peptide,  and (c) saturation phase- corresponding to 
stabilization of Aβ fibril formation. A compound which can decrease the in tensity of the 
fluorescence at these phases can be considered as an inhibitor of Aβ1-40 aggregation. 
Orange G exhibits a concentration-dependent decline in the fluorescence intensity which indicates 
its ability to reduce Aβ1-40 fibril load. At 25 μM, it was able to reduce the growth and saturation 
phase significantly suggesting its ability to interact with various Aβ1-40 aggregates and prevent 
fibril formation (Figure 4.7 (a)).  The aggregation kinetics profile of 5d exhibited a similar trend 
with a concentration-dependent decline in the fluorescence intensity (Figure 4.7 (b)). Compound 
5d was able to prevent the growth phase and reduce Aβ1-40 aggregation similar to orange G.  The 
kinetic aggregation curves suggest that compound 5d is capable of interacting with lower order 






   
Figure 4-7: (a) Aggregation kinetics of orange G at 1, 5 and 25 μM in the presence of Aβ1-40 (5 
μM) over a period of 24 h in phosphate buffer pH 7.4, at 37 ºC; (b) Aggregation kinetics of 
compound 5d at 1, 5 and 25 μM in the presence of Aβ1-40 (5 μM) over a period of 24 h in phosphate 
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4.2.2: Molecular docking studies of PPI derivatives with Aβ1-40   
 
Compound 5d was found to be the most potent compound in the series with ~85% inhibition at 25 
μM for Aβ40 aggregation. Compound 5d was studied for its interaction with dimer and fibril 
models of the Aβ40 peptide (PDB:2LMN). Molecular docking of 5d with dimer model of the Aβ40 
is given in Fig.4-8 and 4-9. It was observed that 5d was interacting with both the C- and N-terminal 
amino acids of the dimer assembly. Aβ40 forms a “U” shaped conformation which consists of a 
long arm, a short arm and the bend which connects the long and the short arm.  The long arm spans 
the region made up of amino acids Asp1 to Val24 followed by amino acids Gly25 to Lys28 which 
forms the turn region of the peptide. The short arm of the dimer model consists of amino acids 
Gly29 to Val40. 53,113  
 





5d was observed to interact with Ala21 (part of the long arm) via pi-alkyl interactions (distance 
~4.8Å). Ala21 also forms the part of the KLVFFA region in Aβ which is known to be the seeding 
point of the Aβ aggregation. The interaction of 5d with 
Ala21 could be crucial in its ability to prevent Aβ40 
aggregation. At the C-terminal end, pi-alkyl interactions 
were observed with Ile32 (distance ~4.4Å), and strong 
hydrogen bonding was seen between OMe group of 5d and 
the NH and the carbonyl (C=O) groups of Val36 (distance~ 
2.4Å). These interactions might stabilize the dimer 
assembly and prevent further aggregation.  
 
Figure 4-9: A Closer look at the interactions of 5d with amino acids present in Aβ1-40 dimer 
model. 
 
Docking studies of compound 5d with the fibril model of Aβ9-40 (PDB:2LMN) (Fig. 4-10) show 





Figure 4-10: Molecular docking studies of compound 5d with  (a) Fibril model of Aβ9-40  (b) 
Closer look at the interactions of 5d with amino acids present in Aβ9-40 fibril model.  
 
Compound 5d was found to be primarily interacting with the C-terminal amino acids of the Aβ40 
peptide sequence i.e. Gly33 to Met35. Amide-Pi stacking between the Gly33, and Leu34 with 
compound 5d was found to be the most favorable type of interactions with an average distance of 
~3.8Å. Strong hydrogen bonding (distance~2.9Å) between the carbonyl oxygen at the C1 position 
with the free NH group of the Leu34 made the molecular assembly between 5d- Aβ9-40 fibril 
structure stable. Compound 5d also formed pi-sulfur interactions with Met35 (distance~ 5.6Å), 
which is known to play an important role in the reduction of metal ions such as Cu2+ and Fe3+. This 
reduction of metal ions is known to initiate Aβ induced oxidative stress cascade.31,67,70  These 
observations suggest that the PPI derivative 5d can interact with the Aβ40 fibril assembly 




4.2.3: Activity of PPI derivatives toward Aβ1-42 aggregation 
 
The Aβ42 aggregation studies for PPI derivatives 5a-n were conducted at four different 
concentrations (1, 5, 10 and 25 μM) and compared with orange G and resveratrol. In general PPI 
derivatives exhibited better inhibition of Aβ42 at all concentrations tested compared to their 















Table 4-3: Aβ1-42 aggregation inhibition activity of PPI derivatives 5a-n 
 
The results are expressed as average ± SD (n = 3) for three independent experiments. The 
aggregation kinetics assays were carried out using a ThT-based fluorescence assay (excitation = 
440 nm and emission = 490 nm) in the presence of 5 μM of Aβ1-42 in phosphate buffer pH 7.4 at 
37 ºC with shaking over a period of 24 h. N.D – Not determined, P.A.- promotes aggregation.  
 
Compound R R’ % 
inhibition 
at 1 μM 
% 
inhibition 
at 5 μM 
% inhibition 
at 10 μM 
% 
inhibitio
n at 25 
μM 
5a H H 34.7 40.0 64.3 75.8 
5b H 4-OH 36.5 56.7 70.1 76.3 
5c H 4-OMe 40.0 51.9 63.1 70.5 
5d H 3,4-diOMe 41.7 48.9 67.8 90.0 
5e H 3-OMe P.A. 1.5 N.D 10.7 
5f H 3,4,5-
triOMe 
57.4 45.1 56.6 72.9 
5g H 3-OH P.A. 8.4 32.4 54.2 
5h H 2-OMe 52.1 43.9 66.1 93.8 
5i H 2,4-diOMe 61.2 59.9 80.7 N.D 
5j H 2.5-diOMe 55.8 44.2 52.5 71.1 
5k H 4-OH, 3-
OMe 
41.5 48.6 64.4 62.7 
5l H 3-OH, 4-
OMe 
34.3 61.1 73.3 74.5 
5m 9-OMe H P.A. P.A. P.A. P.A. 
5n 8-OMe H P.A. 35.6 N.D. 54.2 
Orange-G   59.0 69.4 79.4 90.0 




The C3 phenyl substituted compound 5a exhibited a gradual increase in Aβ42 inhibition with the 
maximum inhibition seen at 25 μM (75.8% inhibition, Table 4-3). Incorporating OMe groups at 
either ortho, meta or para-position of the C3 phenyl ring provided contrasting results with 
compound 5c exhibiting a concentration-dependent inhibition whereas 5e  exhibited either none 
or weak inhibition at 25 μM (Table 4.3). Compound 5h showed excellent inhibition (93.8% 
inhibition at 25 μM) and exhibited better inhibition compared to the reference agents orange G and 
resveratrol (Table 4.3). The presence of di-OMe substituents in compounds 5d (Fig. 4-11(b)), 5i 
and 5j provided good to excellent inhibition ranging from 40-90% (Table 4-3). The presence of 
3,4,5-tri-OMe phenyl substituent in 5f provide consistent and good inhibition of Aβ42 aggregation 
at all the compound concentrations tested (45-73% inhibition range, Table 4.3). The presence of 
phenolic groups at the C3 position provided mixed results with the compound 5b (R1 = 4-
hydroxyphenyl) exhibiting similar inhibition profile as the unsubstituted compound 5a (R1 = 
phenyl, Table 4-3), whereas compound 5g (R1 = 3-hydroxyphenyl) was less potent compared to 
5b. The C7 and C8 OMe substituted compounds (indole ring) 5m and 5n showed either no or weak 
inhibition (Table 3). In other SAR modification, the presence of either a C3 4-hydroxy-3-
methoxyphenyl or a 4-methoxy-3-hydroxyphenyl substituent provided good inhibition 






Figure 4-11: (a) Aggregation kinetics of orange G at 1, 5 and 25 μM in the presence of Aβ42 (5 
μM) over a period of 24 h in phosphate buffer pH 7.4, at 37 ºC; (b) Aggregation kinetics of 
compound 5d at 1, 5 and 25 μM in the presence of Aβ1-42 (5 μM) over a period of 24 h in phosphate 
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4.2.4: Molecular docking studies of PPI derivatives with Aβ1-42   
 
Figure 4-12: Molecular docking studies of compound 5d with dimer model of Aβ42 (PDB:2NAO)  
 
Compound 5d was found to be the most potent compound in the series with ~90% inhibition at 25 
μM for Aβ42 aggregation. Compound 5d was studied for its interaction with dimer models of the 
Aβ42 peptide (PDB:2NAO). Molecular docking of 5d with dimer model of the Aβ42 is given in 
Fig. 4-12. It was observed that 5d was interacting with the KLVFFA region of the dimer assembly. 
5d was found to interact with Lys16 via hydrogen bonding interactions (distance ~1.85Å). Lys16 
forms the part of the KLVFFA region in Aβ which is known to be the seeding point of the Aβ 
aggregation. The interaction of 5d with Lys16 could be crucial in its ability to prevent Aβ42 









Our studies show that PPI derivatives exhibit anti-Aβ aggregation properties. More significantly, 
they had activity toward both Aβ40 and Aβ42 peptides which is highly desirable as Aβ42 
aggregates are known to be relative more toxic compared to Aβ40 aggregates (Reference). To our 
satisfaction, the core PPI template with a C3 phenyl ring (compound 5a), itself exhibited dual 
inhibition of Aβ40/Aβ42 aggregation ranging from 67-76% inhibition at 25 μM. Furthermore, the 
presence of a C3 3,4-dimethoxyphenyl substituent in 5d (3-(3,4-dimethoxyphenyl)pyrazino[1,2-
a]indol-1(2H)-one, Fig. 4-13) provided excellent inhibition of both Aβ40 and Aβ42 aggregation 
with 83% and 90% respectively at 25 μM. 
  
5d (3-(3,4-dimethoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one) 
% inhibition Aβ40 (at 25 μM) = 83% 
% inhibition Aβ42 (at 25 μM) = 90% 






4.3: Antioxidant activity 
The antioxidant activity of some of the selected compounds was evaluated using DPPH assay 
method, and the results were compared with standard compounds with known antioxidant activity 
such as Trolox, resveratrol, and curcumin.91,92 It was observed that compounds based on PPI 
template exhibit antioxidant activity as shown in Table 4.4. The C3 phenyl substituted compound 
5a itself exhibited antioxidant activity (33-34% DPPH scavenging, Table 4.4, Fig. 4-14) which 
suggests that the core PPI template itself has antioxidant activity. The phenolic compound 5b 
exhibited better antioxidant activity (46% and 55% DPPH scavenging at 25 μM and 50 μM, Table 
4.4) compared to 5a. Compound 5d which exhibited excellent Aβ40/42 inhibition also exhibited 
good antioxidant activity (~48% DPPH scavenging at 50 μM). The best compound in the series 
was compound 5k which possess an antioxidant pharmacophore at the C3 position (R1 = 4-
hydroxy-3-methoxyphenyl) and exhibited ~56% and 83% scavenging at 25 and 50 μM 
concentrations respectively. It was able to exhibit superior antioxidant activity compared to the 
known antioxidant resveratrol (49% and 64% DPPH scavenging at 25 μM and 50 μM, Table 4.4). 
These studies show that PPI templates possess inherent antioxidant activity and are a suitable 

































Table 4-4: DPPH radical scavenging activity of PPI derivatives 
 
Results are obtained as average ± s.d. (n = 3) for two independent experiments. The test compounds 
(25 and 50 μM) were incubated with DPPH (56 μM) at r.t for one h, and the absorbance was 
measured at 517 nm.  
4.4: Transmission electron microscopy (TEM) 
 
TEM imaging on Aβ peptides was carried out in the presence of best PPI derivatives based on the 
aggregation kinetics assay results to study Aβ aggregate morphology after 24 h of incubation at 
370C.110 A 1:1 ratio of Aβ (25 μM) to test compound (25 μM) was used to prepare copper mesh 
grids. The grids were analyzed and compared with a control group which did not include any test 
Compound R R’ % DPPH 
Scavenging at 25 
μM 
% DPPH Scavenging 
at 50 μM 
5a H H 33.9 32.8 
5b H 4-OH 46.3 54.7 
5d H 3,4-diOMe 38.8 47.8 
5f H 3,4,5-triOMe 35.8 38.4 
5g H 3-OH 31.9 32.8 
5h H 2-OMe 24.4 26.8 
5k H 4-OH, 3-OMe 55.4 83.2 
5l H 3-OH, 4-OMe 37.7 50.0 
TROLOX   61.4 96.2 
Resveratrol   48.5 64.1 




compound. The images are shown in Figure 4-15. In the absence of test compounds Aβ40 and Aβ42 
aggregates and forms fibrils when incubated at 37 ºC for 24 h (Figure4-15 (a) and (c)). In the 
presence of orange G (25 μM) a significant reduction is fibril content in seen (Figure4-15 (d)). 
Strikingly, in the presence of our best PPI compound 5d and 5h, we observed a drastic reduction 
in Aβ40 Aβ42 aggregation and fibril load (Figure4-15 (b) (e) and (f)) indicating its potent anti-
aggregation effect. These studies show the anti-Aβ potential of PPI derivatives. 
         
  
   
Figure 4-15: TEM images of Aβ40 alone (a); Aβ40 in the presence of 25 μM  compound 5d; (c) 
Aβ42 alone; Aβ42 in the presence of 25 μM orange G and (d);  Aβ42 in the presence of 25 μM of 








Chapter 5. Conclusions and Future Directions 
5.1 Conclusions 
This MSc thesis project embarked on the design and synthesis of small molecule library based on 
a 3-phenylpyrazino[1,2-a]indol-1(2H)-one (PPI) ring template as novel anti-AD agents. PPI 
compounds 5a-n were synthesized using straightforward and efficient chemistry. The biological 
evaluation included the following in vitro assays: Cholinesterase enzyme (AChE/BuChE) 
inhibition assay, amyloid-beta (Aβ40 and Aβ42)  aggregation inhibition assay and assessing their 
antioxidant properties.  
The PPI template was considered based on the previous literature which has shown that fused 
tricyclic ring systems exhibit cholinesterase inhibition and preliminary modeling studies. 
Furthermore, research from Dr. Nekkar’s lab and other groups has demonstrated that fused 
tricyclics rings can be modified by SAR studies to incorporate multi-targeting potential including 
dual cholinesterase inhibition, Aβ aggregation inhibition and antioxidant properties which are 
involved in AD pathophysiology.    To assess the potency of the PPI ring system as a multi-target 
template for the modulation of different aspects of AD, compounds 5a-n were synthesized with 
good yields (65-75%). In vitro biological evaluations for the synthesized compound library was 
carried out using previously developed and optimized protocols. The biological profiles for the 
synthesized compounds (5a-n) wase obtained using human AChE and BuChE enzymes, Aβ40 and 
Aβ42 aggregation inhibition, as well as antioxidant properties for selected compounds. Molecular 
modeling studies were also conducted to better understand the binding patterns of the compounds 




of PPI derivatives by TEM experiments. A brief summary of the physicochemical properties and 
biological activity data for the synthesized PPI compound library (5a-n) is given below:  
Molecular Weights (MW): 189.69- 294.97 Å3 
Partition coefficient (ClogP): 2.97- 3.69 
AChE Inhibition (IC50): 6.3- 8.7 μM 
BuChE Inhibition (IC50): 1.9- 50 μM 
Aβ40 aggregation inhibition (%inhibition at 25 μM): 17.4- 83.3% 
Aβ42 aggregation inhibition (%inhibition at 25 μM): 10.2- 93% 
Antioxidant capacity (% inhibition at 25 μM): 24- 55.4% 
Antioxidant capacity (% inhibition at 50 μM): 26-83.2% 
 
All the final compounds synthesized based on the novel PPI ring system (5a-n) showed moderate 
activity toward the AChE (IC50 = 6-9 μM). While only ~65% of the compounds (nine out of 
fourteen compounds synthesized) exhibited weak inhibitory properties towards BuChE (IC50 = 
~15-20 μM). It was also observed that thirteen out of fourteen compounds showed some selectivity 
toward AChE inhibition, except for compound 5h [3-(2-methoxyphenyl)pyrazino[1,2-a]indol-
1(2H)-one] - which showed a strong BuChE selectivity with an IC50 value of 1.9 μM and it was 
the most potent BuChE inhibitor identified. Compound 5h exhibited better BuChE inhibition that 
the reference drugs donepezil and rivastigmine. Compounds 5m [9-methoxy-3-




most potent AChE inhibitor (AChE IC50 ~ 6.3 μM) and had no observed activity towards BuChE 
activity (IC50  > 50 μM). The best compound in the series which exhibited dual AChE/ BuChE 
inhibitory properties was compound 5h (AChE IC50 = 7.3 μM; BuChE IC50 = 1.9 μM).  
The PPI derivatives 5-o were also screened for their potential inhibitory properties toward the 
aggregation of Aβ40 and Aβ42. In the case of Aβ40 aggregation inhibition, most of the compounds 
exhibited very good inhibitory properties (17-84% inhibition). About ~65% of the compounds 
(nine out of fourteen compounds synthesized) exhibited more than 50% inhibition in Aβ40 
aggregation at 25 μM. Compound 5d [3-(3,4-dimethoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one] 
was identified as the best compound in the series with ~84% inhibition of the Aβ40 aggregation at 
25 μM and was better than the reference agent orange G (~59% inhibition at 25 μM).    All the 
synthesized compounds were also tested for inhibition of the Aβ42 aggregation. Interestingly, more 
than 85% of the compounds (twelve out of fourteen compounds) exhibited more than 50% 
inhibition at 25 μM concentration. The average range of inhibition for Aβ42 aggregation was 
observed to lie in the range of ~10 to 94%. Compounds 5d [3-(3,4-dimethoxyphenyl)pyrazino[1,2-
a]indol-1(2H)-one]and 5h [3-(2-methoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one] became the 
best compounds in the series with ~90% and 94% inhibition at 25 μM respectively. These results 
were found to be at par with the reference compounds orange G and resveratrol (~90% and 92% 
respectively, at 25 μM).  
Eight out of fourteen synthesized compounds were also evaluated for their antioxidant properties 
using DPPH method. The PPI derivatives exhibit moderate to very good antioxidant properties at 
25 μM (% DPPH scavenging: 24.5 to 55.4%) and 50 μM (% DPPH scavenging: 26.8 to 83%). The 
unsubstituted compound 5a also exhibited ~34% antioxidant property. This can be attributed to 




reacting with the DPPH radical. The presence of a 4-hydroxy-3-methoxyphenyl  pharmacophore 
in curcumin gives rise to its excellent antioxidant properties (% DPPH scavenging = 93.2% at 50 
μM). Adding the same pharmacophore to 5a at the C3 phenyl ring in compound 5k [3-(4-hydroxy-
3-methoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one]), drastically improved the antioxidant 
properties (%DPPH scavenging = 83.2% at 50 μM). In conclusion, compounds based on a novel 
3-phenylpyrazino[1,2-a]indol-1(2H)-one ring can be used to design small molecules to target the 
various AD pathologies. Although their cholinesterase inhibition activity is weak, they represent 
a promising class of compounds. Among them, two compounds, namely 5d and 5h exhibit multi-
targeting potential in AD.  
                                                      
 
5h 5d 
IC50 AChE = 7.3 μM IC50 AChE = 7.47 μM 
IC50 BuChE= 1.9 μM IC50 BuChE= 15.18 μM 
% Aβ40 inhibition ~ 65% (at 25 μM) % Aβ40 inhibition ~ 84.7% (at 25 μM) 
% Aβ42 inhibition ~ 94% (at 25 μM) % Aβ42 inhibition ~ 90% (at 25 μM) 
Antioxidant capacity (% inhibition at 50 μM) 
~47.8% 





5.2 Future Directions 
 Establish toxicity profile of the best compounds identified such as 5d and 5h by conducting 
in vitro cell death assays.  
 Structural modifications of compound 5h by replacing the ortho-OMe-phenyl with 2,6-di-
ortho-OMe-phenyl, ortho-OH-phenyl and 2,6-di-ortho-OH-phenyl substituents to 
understand the contribution of ortho-OMe toward BuChE selectivity.   
Expansion of the compound library by structural modification of the PPI template. The addition 
of various groups at the C3 position such as substituted pyridine ring system or a five and seven-
membered heterocyclic ring system (Figure 5.1) will provide SAR data on structure requirements 
for multi-targeting activity. Other proposed modifications include changing the steric and 
electronic properties at C4, C6, C7, C8, C9 and C10 positions.  
                                                                 
R = H      
R’ =H, -Me, -Et, n-alkyl  
R’’ = H, OH, Cl, NH2, NHMe  






Chapter 6. Experimental  
 
6.1 Chemistry 
All the chemicals were purchased from Sigma-Aldrich® or Acros Organics® and were more than 
95% pure and were used without further purification. Thin layer chromatography (TLC) was 
performed using silica gel 60 F254 (Merck), and spot visualization was done by short (254 nm) or 
long (365 nm) wavelength. Column chromatography was carried out using Merck 230-400 mesh 
silica gel. Melting points were determined using the digital melting point apparatus from REACH 
Devices, USA. 1H and 13C NMR were performed on a Bruker Avance spectrometer (Department 
of Chemistry, University of Waterloo) using CDCl3 or DMSO-d6 as the solvent. Coupling 
constants (J-values) were recorded in Hertz (Hz). Abbreviation used to represent NMR signals 
were s – singlet, d – doublet, t – triplet, m – multiplet, br – broad. Low-resolution mass 
spectrometry (LRMS) data was obtained using Single Quad LC-MS (1260 infinity model), Agilent 
Technologies. The purity of the compound was determined using Agilent 6100 series single quad 
LCMS equipped with an Agilent 1.8 μm Zorbax Eclipse Plus C18 (2.1 x 50 mm) running 30:70 
Water: ACN with 0.1% FA with a flow rate of 0.2mL/min. All the final compounds (5a-n) were 
more than 95% pure. 
General procedure for the synthesis of substituted ethylindole-2-carboxylates (2a-c) 
100 mL round bottom flask was charged with 6.2 mmol of indole-2-carboxylic acids (1a-c). To 
the reaction flask, 40 mL of anhydrous ethanol was added along with 1ml of conc. H2SO4. The 
reaction mixture was refluxed for 24 h at 78 0C. After the reflux, the solvent was removed in vacuo 
to give the crude product which was then re-dissolved in 25 mL of ethyl acetate and then 




NaHCO3 solution, and then the organic layer was washed three times with 25 mL of saturated 
brine solution. The organic layer was then dried over anhydrous MgSO4, and the solvent was 
removed in vacuo to yield the crude product which was then further purified using silica gel flash 
column chromatography using 100% DCM as an eluent.  
Ethyl 1H-indole-2-carboxylate (2a): This compound was synthesized by esterification of 1a as 
per the method given above to give white solid product. (83.8%), mp: 120-122°C. 1H NMR 
(CDCl3, 300 MHz): δ = 1.39 (t, 3H, J = 7.1 Hz), 4.37 (q, 2H, J = 7.1 Hz), 7.12 (t, 1H, J = 7.2 Hz), 
7.24-7.22 (m, 1H), 7.29 ( t, 1H, J = 7.0 Hz), 7.40 (d, 1H, J = 8.2 Hz), 7.69 (d, 1H, J = 8.0 Hz), 
8.92 (br, 1H). LRMS (ESI) m/z calc for C11H11NO2 ([M + H]+);189.1 Found 190.2. 
Ethyl 4-methoxy-1H-indole-2-carboxylate (2b): This product was purchased from Alfa Aesar 
and was used without further purification (purity ~96%).   
Ethyl 5-methoxy-1H-indole-2-carboxylate (2c): This product was purchased from Alfa Aesar 
and was used without further purification (purity ~96%).   
General procedure for the synthesis of substituted 2-bromoacetophenones (3a-m) 
To a 250 ml RB flask, 100 mL of dry EtOAc was added followed by the addition of 2 eq. (2.0 
mmol) of CuBr2 and the mixture was stirred for 15 min. at 70 0C. Then 1 eq. (1.0 mmol) of the 
acetophenone dissolved in 10 mL of dry EtOAc was poured into the reaction flask. The reaction 
mixture was refluxed for 12 h at 70 0C, cooled to room temperature and was poured on top of a 
celite bed to filter off the CuBr2 precipitate. The filtered organic layer was collected, washed with 
brine solution (25 mL x 3). The aqueous layer was discarded and the organic layer was collected 
and dried over MgSO4.  Solvent was evaporated in vacuo and the crude product was further 




2-Bromo-1-(4-hydroxyphenyl)ethan-1-one (3b): The product was obtained by brominating 1-
(4-hydroxyphenyl)ethan-1-one using CuBr2   to afford a yellowish product. Mp 116-118 oC (82%). 
1 H NMR (300 MHz, DMSO-d6): δ = 4.47 (s, 2H), 6.82 (d, 2H, J = 9.0 Hz), 7.84 (d, 2H, J = 9.0 
Hz), 10.48 (s, 1H).   
2-Bromo-1-(4-methoxyphenyl)ethan-1-one (3c):  The product was obtained by brominating 1-
(4-methoxyphenyl)ethan-1-one using CuBr2  to afford a yellowish product. Mp 64-66 oC (92.1%). 
1 H NMR (300 MHz, DMSO-d6): δ = 3.83 (s, 3H), 4.80 (s, 2H), 7.02 (d, 2H, J = 9.0 Hz), 7.94 (d, 
2H, J = 7.0 Hz). 
2-Bromo-1-(3,4-dimethoxyphenyl)ethan-1-one (3d): The product was obtained by brominating 
1-(3,4-dimethoxyphenyl)ethan-1-one using CuBr2 to afford a yellowish product. (81.9%). 1 H 
NMR (DMSO-d6, 300 MHz): δ = 3.79 (s, 3H), 3.83 (s, 3H), 4.82 (s, 3H), 7.05 (d, 1H, J = 8.4 Hz), 
7.45 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H). 
2-Bromo-1-(3-methoxyphenyl)ethan-1-one (3e): The product was obtained by brominating 1-
(3-methoxyphenyl)ethan-1-one using CuBr2  to afford a yellowish product. Yield: 77.9%. 1H NMR 
(DMSO-d6, 300 MHz): δ = 3.79 (s, 3H) 4.90 (s, 2H), 7.20 (d, 1H, J = 8.3Hz), 7.41 (m, 2H, J = 7.9 
Hz), 7.54 (d, 1H, J = 7.6 Hz). 
2-Bromo-1-(3,4,5-trimethoxyphenyl)ethan-1-one (3f): The product was obtained by 
brominating 1-(3,4,5-trimethoxyxyphenyl)ethan-1-one using CuBr2 to afford a yellowish product. 
(69.5%). 1H NMR (DMSO-d6, 300 MHz): δ = 3.72 (s, 3H), 3.82 (s, 6H), 4.92 (s, 2H), 7.21 (s 2H).  
2-Bromo-1-(3-hydroxyphenyl)ethan-1-one (3g): The product was obtained by brominating 1-
(3-hydroxyxyphenyl)ethan-1-one using CuBr2  to afford a yellowish product. ( 79.9%). 1H NMR 




2-Bromo-1-(2-methoxyphenyl)ethan-1-one (3h): The product was obtained by brominating 1-
(2-methoxyphenyl)ethan-1-one using CuBr2  to afford a yellowish product. (75.7%). 1H NMR 
(DMSO-d6, 300 MHz): δ = 3.87 (s, 3H), 4.74 (s, 2H), 7.00 (t, J = 7.3 Hz, 1H), 7.14 (d, 1H, J = 8.3 
Hz), 7.53 (t, 1H, J = 6.9 Hz), 7.63 (d, J = 7.7 Hz, 1H). 
2-Bromo-1-(2,4-dimethoxyphenyl)ethan-1-one (3i): The product was obtained by brominating 
1-(2, 4-dimethoxyphenyl)ethan-1-one using CuBr2  to afford a yellowish product. (68%). 1H NMR 
(DMSO-d6, 300 MHz): δ = 3.78 (s, 3H), 3.84 (s, 3H), 4.67 (s, 2H), 6.60-6.64 (m, 2H), 7.68 (d, 1H, 
J = 7.9 Hz). 
2-Bromo-1-(2,5-dimethoxyphenyl)ethan-1-one (3j): The product was obtained by brominating 
1-(2, 5-dimethoxyphenyl)ethan-1-one using CuBr2  to afford a yellowish product. mp?? ( 76.8%). 
1H NMR (DMSO-d6, 300 MHz): δ = 3.70 (s, 3H), 3.82(s, 3H), 4.75 (s, 2H), 7.06- 7.18 (m,  3H). 
2-Bromo-1-(4-hydroxy-3-methoxyphenyl)ethan-1-one (3k):  The product was obtained by 
brominating (4-hydroxy-3-methoxyphenyl)ethan-1-one using CuBr2 to afford a yellowish product. 
(78.2%). 1H NMR (DMSO-d6, 300 MHz): δ = 3.79 (s, 3H), 4.77 (s, 2H), 6.80 (d, 1H, J = 7.2 Hz), 
7.44 (d, J = 7.2 Hz, 1H), 7.61 (d, 1H, J = 7.2 Hz), 10.47 (s, 1H). 
General procedure for the synthesis of OTBDMS protected 2-bromoacetophenones (3b’, g’, 
l’, and m’) 
Hydroxy group containing substituted bromo acetophenones (3.9 mmol; 1eq.) were dissolved in 
20 mL of DCM/ EtOAc (1:1) solution in a 100mL round bottom flask. To this mixture, 7.8 mmol 
(2 eq) of TEA was added dropwise, and the mixture was stirred for five min. at room temperature. 
Then, six mmol (1.5 eq) of TBDMSCl was added directly to the reaction mixture and was stirred 




funnel, and the organic layer was washed with ten mL of 1M HCl solution. The aqueous layer was 
discarded, and the organic layer was collected in an EM flask, and the contents were dried over 
MgSO4. The solvent was removed in vacuo to obtain the crude product which was further purified 
by silica gel chromatography using n-hexanes/ EtOAc (5:1) as eluent.   
2-Bromo-1-(4-((tert-butyldimethylsilyl)oxy)phenyl)ethan-1-one (3b’):  The product was 
obtained by coupling 3b with TBDMSCl to obtain a yellowish liquid ( 58.3%). 1H NMR (DMSO-
d6, 300 MHz): δ = 0.21 (s, 6H), 0.97 (s, 9H), 4.61 (s, 2H), 6.86 (d, 2H, J = 9.0 Hz), 7.88 (d, 2H, J 
= 9.0 Hz).   
2-Bromo-1-(3-((tert-butyldimethylsilyl)oxy)phenyl)ethan-1-one (3g’): The product was 
obtained by coupling 3g with TBDMSCl to afford a yellowish liquid(79.9%). 1H NMR (300 MHz, 
DMSO-d6): δ= 0.21 (s, 6H), 0.97 (s, 9H), 4.83 (s, 2H), 7.02 (d, 1H, J = 6.8 Hz), 7.26 (m, 3H).  
2-Bromo-1-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)ethan-1-one (3k’): The 
product was obtained by coupling 3k with TBDMSCl to afford a yellowish liquid (51%), 1H NMR 
(300 MHz, DMSO-d6): δ = 0.17 (s, 6H), 0.98 (s, 9H), 3.84 (s, 3H), 4.63 (s, 2H), 6.85 (d, 1H, J = 
7.2 Hz), 7.41 (d, 1H, J = 7.2 Hz), 7.50 (s, 1H). 
2-Bromo-1-(3-((tert-butyldimethylsilyl)oxy)-4-methoxyphenyl)ethan-1-one (3l’): The product 
was obtained by coupling 3l with TBDMSCl to afford a yellowish liquid and was used without 
purification.  
General procedure for the synthesis of substituted ethyl-1-(2-oxo-2-phenylethyl)-1H-indole-
2-carboxylates (4a-n) 
One eq. (4.8 mmol) of ethylindole-2-carboxylates (2a-c) was charged in a 250 mL RB flask to 




material dissolves. To the above reaction mixture, two equivalents (9.6 mmol) of cesium carbonate 
(CS2CO3) was added, and the reaction mixture was kept under stirring at 70 0C for fifteen minutes. 
To the above mixture, KI was added in catalytic quantities (~10-15mg) after which the 1.2 eq. of 
(5.79 mmol) of substituted 2-bromoacetophenones (3a-m) was added, and the reaction mixture 
was refluxed for 24 h at 70 °C, cooled to r.t., the contents were transferred to a separatory funnel, 
and the reaction mixture was diluted with 25 mL of EtOAc. The organic layer was washed with 
brine solution (20 mL x 3 ), and the organic layer was dried over MgSO4. The solvent was removed 
in vacuo and the crude product obtained was further purified by silica gel column chromatography 
using n-hexanes/ EtOAc (5:1) to afford yellowish products.  The analytical data is given below; 
Ethyl 1-(2-oxo-2-phenylethyl)-1H-indole-2-carboxylate (4a) 
The product was obtained by coupling 2a with 3a by the method mentioned above to afford a 
yellowish solid product (460 mg, yield: 31.2%). mp: 118-120 0C. 1H NMR (  CDCl3, 300 MHz): 
δ = 1.29 (t, 3H, J = 7.2  Hz), 4.23 (q, 2H, J = 7.2 Hz), 6.03 (s, 2H), 7.12- 7.32 (m, 4H), 7.41 (s, 
1H), 7.49 (t, 1H, J = 7.2 Hz), 7.60 (t, 1H, J = 7.2 Hz), 7.69 ( d, 1H, J = 7.8 Hz), 8.04 (d, 2H, J = 
7.2 Hz,); 13C NMR (CDCl3, 75 MHz): δ = 14.24, 50.93, 60.59, 109.63, 111.14, 120.92, 122.90, 
125.33, 126.24, 127.77, 128.88, 133.71,  135.04, 139.73, 162.29, 193.39.   
Ethyl 1-(2-(4-hydroxyphenyl)-2-oxoethyl)-1H-indole-2-carboxylate (4b):  
The product was obtained by coupling 2a with 3b’ by the method mentioned above to afford a 
yellowish brown solid product (yield: 48.8%). mp: 109-110 0C. 1H NMR (  DMSO-d6, 300 MHz): 
δ = 1.12 (t, 3H, J = 7.1 Hz,), 4.15 (q, 2H, J = 7.1 Hz,), 6.06 (s, 2H), 6.88 (d, 2H, J = 7.4 Hz), 7.26 
(d, 2H, J = 8.1 Hz), 7.31 (d, 1H, J = 8.8 Hz), 7.57 (s, 1H),  7.67 (d, 1H, J = 7.0 Hz),  7.93 (d, 2H, 




Ethyl 1-(2-(4-methoxyphenyl)-2-oxoethyl)-1H-indole-2-carboxylate (4c):  
The product was obtained by coupling 2a with 3c by the method mentioned above to afford a 
yellowish solid product (yield: 39.9%).mp: 108-109 literature value is different 0C. 1H NMR 
(CDCl3, 300 MHz): δ = 1.29 (t, 3H, J = 7.1 Hz,), 3.88 (s, 3H), 4.23 (q, 2H, J = 7.1 Hz,), 5.98 (s, 
2H), 6.96 (d, 2H, J = 6.9 Hz), 7.14- 7.29 (m, 3H, J = 8.3 Hz), 7.40 (s, 1H),  7.68 (d, 1H, J = 7.9 
Hz),  8.01 (d, 2H, J = 6.9 Hz).  
Ethyl 1-(2-(3,4-dimethoxyphenyl)-2-oxoethyl)-1H-indole-2-carboxylate (4d):  
The product was obtained by coupling 2a with 3d by the method mentioned above to afford a 
yellowish solid product. mp: 180-182 0C (25.7%). 1H NMR (300 MHz,  CDCl3): δ = 1.23 (t, 3H, 
J = 7.1 Hz,), 3.89 (s, 3H), 3.96 (s, 3H), 4.23 (q, 2H, J = 7.1 Hz), 6.00 (s, 2H), 6.92 (d, 1H, J = 8.3 
Hz), 7.14- 7.32 (m, 3H), 7.40 (s, 1H), 7.52 (s, 1H), 7.68 (t, 2H, J = 8.5 Hz).  
Ethyl 1-(2-(3-methoxyphenyl)-2-oxoethyl)-1H-indole-2-carboxylate (4e)  
The product was obtained by coupling 2a with 3e by the method mentioned above to afford a 
yellowish solid product (yield:14%). This compound was taken to the next step without further 
purification.  
Ethyl 1-(2-(3,4,5-trimethoxyphenyl)-2-oxoethyl)-1H-indole-2-carboxylate (4f):  
The product was obtained by coupling 2a with 3f by the method mentioned above to afford a 
yellowish solid product (yield:15.9%). mp: 115-116 0C. 1H NMR (300 MHz, CDCl3): δ = 1.31 (t, 
3H, J = 7.1 Hz,), 3.83 (s, 3H), 3.89 (s, 6H), 4.24 (q, 2H, J = 7.1 Hz,), 5.99 (s, 2H), 7.13-7.33 (m, 
5H), 7.40 (s, 1H),  7.69 (d, 1H, J = 7.8 Hz).  




The product was obtained by coupling 2a with 3g by the method mentioned above to afford a 
yellowish solid product (yield: 31.2%). This compound was taken to the next step without further 
purification.  
Ethyl 1-(2-(2-methoxyphenyl)-2-oxoethyl)-1H-indole-2-carboxylate (4h) 
The product was obtained by coupling 2a with 3h by the method mentioned above to afford a 
yellowish solid product (yield: 14%).  This compound was taken to the next step without further 
purification.  
Ethyl 1-(2-(2,4-dimethoxyphenyl)-2-oxoethyl)-1H-indole-2-carboxylate (4i):  
The product was obtained by coupling 2a with 3i by the method mentioned above to afford a 
yellowish solid product (yield: 37.5%). mp: 109-110 0C. 1H NMR (300 MHz,  CDCl3): δ = 1.28 
(t, 3H, J = 7.1 Hz,), 3.86 (s, 3H), 4.00 (s, 3H), 4.22 (q, 2H, J = 7.1 Hz,), 5.90 (s, 2H), 6.54-6.52 
(m, 2H), 7.09 (t, 1H, J = 7.1 Hz), 7.20-7.33 (m, 2H), 7.38 (s, 1H), 7.67 (d, 1H, J = 7.9 Hz), 7.92 
(d, 1H, J = 8.7 Hz). 
Ethyl 1-(2-(2,5-dimethoxyphenyl)-2-oxoethyl)-1H-indole-2-carboxylate (4j):  
The product was obtained by coupling 2a with 3j by the method mentioned above to afford a 
yellowish solid product ( yield: 22.0%). mp: 118-120 oC. 1H NMR (300 MHz,  CDCl3): δ = 1.29 
(t, 3H, J = 7.1 Hz,), 3.75 (s, 3H), 3.98 (s, 3H), 4.23 (q, 2H, J = 7.1 Hz), 5.95 (s, 2H), 6.96 (d, 1H, 
J = 9.0 Hz), 7.07- 7.16 (m, 2H), 7.22- 7.40 (m, 3H), 7.38 (s, 1H), 7.68 (d, 1H, J = 7.9 Hz).  




The product was obtained by coupling 2a with 3k by the method mentioned above to afford a 
yellowish solid product (yield: 75.2%). This compound was taken to the next step without further 
purification.  
Ethyl 1-(2-(3-hydroxy-4-methoxyphenyl)-2-oxoethyl)-1H-indole-2-carboxylate (4l) 
The product was obtained by coupling 2a with 3l by the method mentioned above to afford a 
yellowish product (yield: 42%). mp: 174-175 0C. 1H NMR (300 MHz,  DMSO-d6): δ = 1.11 (t, 
3H, J = 7.1 Hz,), 3.86 (s, 3H), 4.15 (q, 2H, J = 7.1 Hz,), 6.04 (s, 2H), 7.07- 7.11 (m, 2H), 7.31- 
7.40 (m, 2H), 7.40 (s, 1H), 7.55 (d, 1H, J = 7.9 Hz), 7.67- 7.70 (m, 2H), 9.43 (s, 1H). 
Ethyl 4-methoxy-1-(2-oxo-2-phenylethyl)-1H-indole-2-carboxylate (4m)  
The product was obtained by coupling 2b with 3a by the method mentioned above to afford a 
yellowish solid product (yield: 45.5%). This compound was taken to the next step without further 
purification.  
Ethyl 5-methoxy-1-(2-oxo-2-phenylethyl)-1H-indole-2-carboxylate (4n)  
The product was obtained by coupling 2c with 3a by the method mentioned above to afford a 
yellowish solid product (yield: 42.3%). This compound was taken to the next step without further 
purification.  
 
General procedure for the synthesis of substituted 3-phenylpyrazino[1,2-a]indo-1(2H)-ones 
(5a-n) 
1 eq. (0.64 mmol) of ethyl 1-(2-oxo-2-phenylethyl)-1H-indole-2-carboxylate (4a-o) was loaded in 
a pressure vial (PV) and to it 10 eq. (6.4 mmol) of CH3COONH4was added. Then, n-BuOH (4 ml) 




h at 150 °C.  After which the reaction mixture was cooled and diluted with 15 mL of EtOAc. The 
contents were transferred in a sepratory funnel, treated ith 10 mL of saturated NaHCO3 solution.  
The organic layer was washed successively with brine solution, organic layer was collected, dried 
over MgSO4 and filtered. The solvent was removed in vacuo to give yellow to dark orange product 
which was further purified by either crystallization using n-hexanes- ethyl acetate solution (5:1) 
or by using silica column chromatography (EtOAc: MeOH -9:1)) . The analytical data is given 
below: 
3-Phenylpyrazino[1,2-a]indol-1(2H)-one (5a) 
 This compound was prepared by the cyclization of 4a using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above to yield light yellow solid 
(110 mg, 76%). mp:  208-210 0C. 1H NMR (300 MHz, CDCl3) δ = 7.30 (t, 1H, J = 7.2 Hz), 7.41- 
7.58 (m, 8H), 7.70 (d, 1H, J = 8.4 Hz), 7.83 (d, 1H, J = 8.1 Hz), 8.13 (br, 1H). LRMS (ESI) m/z 
calc for C17H12N2O ([M + H]+); 260.1 Found 261.0  
3-(4-Hydroxyphenyl)pyrazino[1,2-a]indol-1(2H)-one (5b)  
This compound was prepared by the cyclization of 4b using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above to yield light yellowish 
orange solid (90 mg, 66.1%). mp:  190-192 0C.  1H NMR (300 MHz, DMSO-d6)  δ 6.83 (d, 2H, J 
= 5.5 Hz), 7.21- 7.28 (m, 2H), 7.37 (d, 1H, J = 7.0 Hz), 7.56 (d, 2H, J = 7.0 Hz), 7.80 (s, 1H) 8.06 
(s, 1H), 8.16 (d, 1H, J = 5.0 Hz), 9.70 (s, 1H), 10.92 (s, 1H).  LRMS (ESI) m/z calc for C17H12N2O2 





 This compound was prepared by the cyclization of 4c using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above to yield light yellowish 
orange solid (110 mg, 71.1%). mp  > 2500C.  1H NMR (300 MHz, DMSO-d6)  δ 3.78 (s, 3H), 7.00 
(d, 2H, J = 8.7 Hz), 7.23 (s, 1H), 7.26 (d, 1H, J = 7.6 Hz), 7.35 (t, 1H, J = 7.5 Hz), 7.69 (d, 2H, J 
= 8.7 Hz), 7.78 (d, 1H, J = 7.9 Hz) 8.11 (s, 1H), 8.15 (d, 1H, J = 8.3 Hz), 10.97 (s, 1H).  LRMS 
(ESI) m/z calc for C18H14N2O2 ([M + H]+); 290.1. Found 291.0. 
3-(3,4-Dimethoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one (5d) 
 This compound was prepared by the cyclization of 4d using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above yield light yellowish orange 
solid (110 mg, 69.1%). mp:  > 2500 C. 1 H NMR (300 MHz, CDCl3): δ = 3.94 (s, 3H), 4.00 (s, 3H), 
6.96 (d, 1H, J = 8.2 Hz), 7.11- 7.17 (m, 2H), 7.29 (t, 1H, J = 7.0 Hz), 7.40 (t, 3H, J = 7.0 Hz,), 
7.71 (d, 1H, J = 8.4 Hz), 7.82 (d, 1H, J = 8.0 Hz), 8.82 (br, 1H). LRMS (ESI) m/z calc for 
C19H16N2O3 ([M + H]+); 320.1. Found 321.0. 
3-(3-Methoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one (5e) 
 This compound was prepared by the cyclization of 4e using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above to yield light yellowish 
orange solid (100 mg, 70.4%). mp:  >2500C.  1H NMR (300 MHz – CDCl3) δ 3.89 (s, 3H), 6.89 
(d, 2H, J = Hz), 7.09 (s, 1H), 7.14 (d, 1H, J = 7.1 Hz), 7.30- 7.35 (m, 2H), 7.38- 7.45 (m, 3H), 7.53 
(s, 1H), 7.70 (d, 2H, J = 8.2 Hz), 7.83 (d, 1H, J = 7.7 Hz) 8.26 (s, br,1H).  LRMS (ESI) m/z calc 





This compound was prepared by the cyclization of 4f using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above yield yellow solid (120 mg, 
68.8%). mp:  >2500C. 1 H NMR (300 MHz, CDCl3): δ = 3.91 (s, 3H), 3.98 (s, 6H), 6.83 (s, 2H), 
7.31 (t, 1H, J = 7.0 Hz), 7.41-7.49 (m, 3H), 7.73 (d, 1H, J = 8.4 Hz), 7.83 (d, 1H, J = 8.0 Hz), 9.21 
(br, 1H). LRMS (ESI) m/z calc for C20H18N2O4 ([M + H]+); 350.1 Found 351.0.  
3-(3-Hydroxyphenyl)pyrazino[1,2-a]indol-1(2H)-one (5g)  
This compound was prepared by the cyclization of 4g using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above yield light yellowish solid 
(100 mg, 80.1%) mp:  235-2370C, 1H NMR (300 MHz, DMSO-d6) δ 6.83 (d, 1H, J = 7.1 Hz), 
7.12- 7.28 (m, 5H), 7.36 (d, 1H, J = 7.6Hz), 7.78 (s, 1H), 8.14 (s, 1H), 8.18 (d, 1H, J = 7.1 Hz), 
9.58 (s, 1H), 10.96 (s, 1H).  LRMS (ESI) m/z calc for C17H12N2O2 ([M + H]+); 276.1. Found 277.1 
 
3-(2-Methoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one (5h)  
This compound was prepared by the cyclization of 4h using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above yield light yellow solid 
(120 mg, 70.5%), mp: 193-194 0C.  1H NMR (300 MHz, DMSO-d6)  δ 3.80 (s, 3H), 7.00 (t, 1H, J 
= 7.4 Hz), 7.10 (d, 1H, J = 8.1 Hz), 7.22 (s, 1H), 7.26 (d, 1H, J = 7.6 Hz), 7.33 (d, 1H, J = 7.4 Hz), 
7.42 (t, 2H, J = 4.3 Hz), 7.78 (d, 1H, J = 7.9 Hz),  7.89 (s, 1H), 8.06 (d, 1H, J = 8.3 Hz), 10.96 (s, 





This compound was prepared by the cyclization of 4i  using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above yield light yellow solid 
(130 mg, 81.1%). mp:  184-185 0C. 1 H NMR (300 MHz, DMSO-d6): δ = 3.80 (s, 6H), 6.58 (d, 
1H, J = 8.3 Hz), 6.60 (s, 1H), 7.20- 7.34 (m, 4H), 7.78 (d, 2H, J = 8.1 Hz), 8.04 (d, 1H, J = 8.3 
Hz), 10.68 (s, 1H). LRMS (ESI) m/z calc for C19H16N2O3 ([M + H]+); 320.1. Found 321.0. 
3-(2,5-Dimethoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one (5j) 
 This compound was prepared by the cyclization of 4j using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above yield light yellow solid 
(120 mg, 75.5%). mp:  178-179 0C. 1 H NMR (300 MHz, CDCl3): δ = 3.83 (s, 3H), 3.87 (s, 3H),  
6.90 (s, 2H), 7.04 (s, 1H), 7.29 (t, 1H, J = 7.2 Hz), 7.39- 7.43 (m, 2H), 7.51 (s, 1H), 7.68 (d, 1H, J 
= 8.7 Hz), 7.82 (d, 1H, J = 7.9 Hz), 8.67 (br, 1H). LRMS (ESI) m/z calc for C19H16N2O3 ([M + 
H]+); 320.1. Found 321.0. 
3-(4-Hydroxy-3-methoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one (5k) 
 This compound was prepared by the cyclization of 4k  using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above yield light yellow solid 
(120 mg, 78.4%). mp:  > 250 0C. 1H NMR (300 MHz, DMSO-d6): δ = 3.86 (s, 3H), 6.81 (d, 1H, J 
= 7.8 Hz), 7.22-7.40 (m, 4H), 7.80 (d, 1H, J = 7.1 Hz), 8.10 (s, 1H), 8.18 (d, 1H, J = 7.2 Hz), 9.24 
(s, 1H), 10.96 (s, 1H). LRMS (ESI) m/z calc for C18H14N2O3 ([M + H]+); 306.1. Found 307.0. 
3-(3-Hydroxy-4-methoxyphenyl)pyrazino[1,2-a]indol-1(2H)-one (5l)  
This compound was prepared by the cyclization of 4l  using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above yield yellow solid (120 mg, 




Hz), 7.15-7.18 (m, 2H), 7.22 (s, 1H), 7.26 (d, 1H, J = 8.2 Hz), 7.37 (s, 1H), 7.77 (d, 1H, J = 8.2 
Hz), 8.04 (s, 1H), 8.16 (d, 1H, J = 8.4 Hz), 9.08 (s, 1H), 10.90 (s, 1H). LRMS (ESI) m/z calc for 
C18H14N2O3 ([M + H]+); 306.1. Found 307.0..  
9-Methoxy-3-phenylpyrazino[1,2-a]indo-1(2H)-one (5m)  
This compound was prepared by the cyclization of 4m using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above yield yellow solid (120 mg, 
78.4%). mp:  >250 0C (78.4%). 1H NMR (DMSO-d6, 300 MHz): δ = 3.92 (s, 3H), 6.73 (d, 1H, J 
=7.7 Hz), 7.17 (s, 1H), 7.29-7.48 (m, 4H), 7.74-7.78 (m, 3H), 8.15 (s, 1H), 11.03 (s, 1H). LRMS 
(ESI) m/z calc for C18H14N2O2 ([M + H]+); 290.1. Found 291.0. 
8-Methoxy-3-phenylpyrazino[1,2-a]indo-1(2H)-one (5n)  
This compound was prepared by the cyclization of 4n using CH3COONH4 (10 eq); n-BuOH and 
AcOH (4:1; 5 mL) as the solvent using conditions as mentioned above yield light yellowish solid 
(120 mg ). mp:  188-189 0C (78.4%). 1H NMR (DMSO-d6, 300 MHz): δ = 3.80 (s, 3H), 7.01 (s, 
1H), 7.06 (d, 1H, J = 7.2 Hz), 7.16 (s, 1H), 7.24 (d, 1H), 7.29 (d, 2H, J = 7.2 Hz), 7.43 (d, 2H, J 
=7.4Hz), 7.75 (d, 1H, J = 8.1 Hz), 8.19 (s, 1H), 11.0 (s, 1H). LRMS (ESI) m/z calc for C18H14N2O2 










6.2 Biological Evaluation 
6.2.1 Cholinesterase assay 
 
The PPI derivatives were tested using a 96-well plate format using tacrine and rivastigmine as 
reference compounds. To each wells, 160 µl of 1.5 mM solution of DTNB was added which was 
prepared using 50 mM Tris-HCl buffer (pH = 8.0; contains 0.1 M NaCl and 0.02 M MgCl2.6H2O). 
To this, 50 µL of the cholinesterase enzyme (human AChE/ BuChE) was added which was 
prepared in a buffer solution of 50 mM Tris-HCl of pH 8.0, containing 0.1% w/v bovine serum 
albumin. Then, different concentrations of the test compound viz. 1, 2.5, 5, 10, 25, 50 µl (1-50 
μM) in DMSO and buffer solution was added to individual wells. The loaded plate was incubated 
at room temperature for 5 min, and then 30 µl of the substrate (ACh/ BuCh) was added. 
Measurements were made by observing the absorbance of each well at 405 nm at 0, 1, 2, and 3 
min time intervals. The blank control well-contained 80 μL of DTNB stock solution, 25μL of 
buffer A solution, 4 μL of DMSO and 15 μL of thiocholine solution (ACSh/ BuSh). While, 100% 
control contained 80 μL of DTNB stock solution, 25 μL of cholinesterase enzymes (AChE/ 
BuChE), 1 μL of DMSO, 4 μL of Buffer A and 15 μL of thiocholine solution (AChT/ BuhT).  
Percent inhibition was calculated using the formula:  
 % 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =  
𝐴𝑏𝑠. 𝑜𝑓 100% 𝑤𝑒𝑙𝑙𝑠 − 𝐴𝑏𝑠. 𝑓𝑟𝑜𝑚 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟 𝑤𝑒𝑙𝑙𝑠
𝐴𝑏𝑠. 𝑜𝑓 100% 𝑤𝑒𝑙𝑙𝑠
 𝑋 100 
IC50 values were calculated plotting the percent inhibition vs. concentration logarithmically, and 
the results were expressed as the mean± standard deviation (SD) of three independent experiments 






6.2.2 Aβ aggregation inhibition assay  
 
The anti-Aβ aggregation activity of PPI derivatives was evaluated using the ThT-based 
fluorescence assay. The Aβ1-40 and Aβ1-42 hexafluoro-2-propanol (HFIP) (rPeptide, USA) stock 
solutions were prepared in 1% ?? NH4OH solution for Aβ1-40 and Aβ1-42 respectively, to obtain a 1 
mg/mL stock solution, followed by dilution in phosphate buffer (pH 7.4) to 500 μM. Stock 
solutions of test compounds were prepared in DMSO and diluted in phosphate buffer (pH 7.4). 
The ThT fluorescent dye stock solution (15 μM) was prepared in 50 mM glycine buffer (pH 7.4). 
The aggregation kinetics assay was carried out using Corning® 386-well flat, clear bottom black 
plates. Each compound containing well was charged with 44 μL of ThT, 20 μl of phosphate buffer 
(pH 7.4), eight μl of test compounds in different concentrations (1, 5, 10 and 50 μM) and eight μl 
of Aβ (5 μM final concentration). The plate was incubated at 37 °C with a plate cover under 
shaking and fluorescence was measured every 5 min. Using a BioTek Multimode 
Microplate Reader (excitation = 440 nm and emission = 490 nm) over a period of 24 h. The known 
Aβ aggregation inhibitor orange G was used as a reference compound. The percentage inhibition 
was calculated using the equation 100% control – [(IFi – IFo)] where 100% control indicates no 
inhibitor, IFi and IFo are the fluorescence intensities in the presence and absence of ThT. The 
results were expressed as percentage inhibition of two separate experiments of triplicate 
measurements. 
6.2.3 Molecular docking  
 
Molecular docking studies were performed using Discovery Studio (DS) Structure-Based-Design, 




structures of AChE (PDB: 4EY7), BuChE (PDB: 2XQJ), Aβ40 (PDB:2LMN) and Aβ42 (2NAO)  
were obtained from the RCSB protein data bank. To the enzyme structure, hydrogens were added.  
Test compounds were built in 3D using Build Fragment tool, and energy minimization was 
performed for 1000 iterations using steepest descent and conjugate gradient minimizations 
respectively. The CDOCKER algorithm in the receptor-ligand interactions was used to dock the 
molecules with appropriate enzymes after defining a 15 Å sphere radius within the enzyme which 
covers all the active site amino acids. CHARMm force field was used for the docking studies. The 
quality of ligand-enzyme complex was evaluated based on CDOCKER Interaction energy and 
CDOCKER energy in kcal/mol. Also, polar and nonpolar interactions were visualized to assess 
the critical interactions involved in compound binding with the respective enzyme/ protein.    
 
6.2.4 Antioxidant activity 
 
 For the antioxidant property evaluation of selected PPI derivatives,  the DPPH radical assay 
method was used, and the results were compared with reference agents Trolox, curcumin, and 
resveratrol. Compound stock solutions were prepared using anhydrous MeOH at 250 μM and 500 
μM concentrations, while, 100mL of DPPH radical stock solution was prepared at 56 μM 
concentration using MeOH. 96 well clear, flat bottom plate was used for carrying out the 
experiments. To each of the wells, 90 μL of DPPH solution followed by 10 μL of the compound 
solution, making the final concentration of the compound as 25 μM and 50 μM in each well. 
Compound control wells contained 90 μL of MeOH and 10 μL of the compound, while, the DPPH 




after 1h of the incubation using a BioTek Synergy H1 microplate reader. The results were 
calculated as % DPPH scavenging using the following formula.  
% 𝐷𝑃𝑃𝐻 𝑠𝑐𝑎𝑣𝑒𝑛𝑔𝑖𝑛𝑔 
=
Absorbance by DPPH control − (absorbance by test compounds − compound control absorbance )
Absorbance by DPPH control
 𝑋 100 
The results were expressed as mean %inhibition ± SD (SD<10%) for two independent experiments 
(n = 3).  
6.2.5 Transmission electron microscopy (TEM) 
 
TEM samples were prepared by incubating the Aβ with appropriate PPI derivatives/ control in a 
Costar® 96 well, black plate with clear bottom. To each of the wells, 80 μL of phosphate buffer 
(215 mM) solution was added, which was followed by 20 μL of  250 μM test compound solution. 
100 μL of a 50 μM solution of Aβ40/42 was then added. Control wells were charged with 18 μL of 
phosphate buffer and 2μL of DMSO. In Aβ40/42 loaded wells, the final Aβ40/42 to test compound 
ratio was 1:1 (at 25 μM). The plate was then incubated on the Fisher plate incubator for 24h, set at 
the temperature of 370C.  
TEM grids were prepared by adding 20 μL of the incubated solution over a Formvar- coated copper 
grids (400 mesh). The grids were subjected to overnight air drying, after which, the grids have 
been submitted to the washing process so as to remove any precipitated buffer salts. This step was 
done by adding ~30 μL of deionized water on top of the grids and quickly blotting the water droplet 
using a small piece of filter paper. The washing step was done twice and a drying period of around 
2h was given between each drying step. After the grids were completely dried, the contents of the 
grids were subjected to the staining process which was done using 2% phosphotungstic acid (PTA). 




and not the entire grid). ~20 μL of PTA was used to stain the grid which was blotted right after the 
addition of the drop of PTA using a small piece of filter paper. After the staining step, the grids 
were air-dried overnight. The TEM screening was done using a Philips CM 10 transmission 
electron microscope at 60 kV (at the Department of Biology, University of Waterloo) and the 
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Sample 1H NMR spectra of compounds 


















Compound 4a 1H NMR (in CDCl3) 































Compound 5d- 1H NMR (in CDCl3) 





Compound 5e- 1H NMR (in CDCl3)   
 
                                                         





Compound 5f- 1H NMR (in CDCl3) 






Compound 5h- 1H NMR (in DMSO-d6)      






Compound 5i- 1H NMR (in CDCl3)  
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